

INDEX

Volume Fifteen—January through December 1981

DRUG INTELLIGENCE AND CLINICAL PHARMACY

JANUARY	Pages 1- 80	JULY/AUGUST	Pages 513- 624
FEBRUARY	Pages 81-160	SEPTEMBER	Pages 625- 720
MARCH	Pages 161-240	OCTOBER	Pages 721- 832
APRIL	Pages 241-320	NOVEMBER	Pages 833- 928
MAY	Pages 321-416	DECEMBER	Pages 929-1032
JUNE	Pages 417-512		

A

Acetaminide, in cardiovascular disease (CTF) 58
Acetaminophen, in toxicology (CTF) 222; teratogenesis, 546
Acetazolamide, in general medicine (CTF) 399
Acetohydroxamic Acid, dissolution of urinary stones, 886
N-acetylprocainamide, in cardiovascular disease (CTF) 1006; ventricular arrhythmias, 398
Ace, clinical trial of topical erythromycin, 372
ACTH, cerebral atrophy, in adverse reactions (CTF) 60
Actinomycosis, disease and treatment, 99
Acyclovir, in infectious disease (CTF) 819, 914; in ophthalmology (CTF) 221
Adams, Harry G. (coauthor) see **Honda, Dennis H.**, 284
Adams, Michael P. (author) complications of topical podophyllum, 280
Adler, David S. (coauthor) see **Kleinberg, Michael L.**, 291
Adverse Effects, allopurinol, reversible flu-like syndrome, leukopenia, and thrombocytopenia, 286; bullae with allopurinol, 490; glaucoma and cataracts associated with drugs and chemicals, table, 438; granulocytopenia with penicillin G, 289; hyperglycemia with propranolol and chlorpromazine, 598; methyldopa-induced hemolytic anemia and parkinsonism, 488; moxalactam, hypoprothrombinemia, 288; oxazepam withdrawal convulsions, 487
Adverse Drug Reactions (CTF), ACTH, cerebral atrophy, 60; alcohol, health hazards, 1009; alfalfa seeds, pancytopenia, 613; aluminum hydroxide, encephalopathy, 401; aminocaproic acid, myoglobinuria, 222; amitriptyline, anxiety, 300; amphotericin B, pulmonary toxicity, 706; amphotericin B, spinal cord damage, 60; amygdalin, no toxicity observed, 401; analgesics, gastric ulcers, 613; antacid, hypermagnesemia, 498; antacids, osteomalacia, 300; antidepressants, effects on cardiovascular function, 706; aspirin, hepatic encephalopathy, 60; bleomycin, skin thickening, 222; bromocriptine, galactorrhea and hyperprolactinemia, 60; buffered aspirin, fecal blood loss, 1009; caffeine, fluid and electrolyte imbalances, 60; calcium gluconate, mania, 60; cancer, drugs associated with, 613; cancer chemotherapy, toxicity, 145; captopril, hepatocellular jaundice, 706; captopril, nephrotic syndrome, 146; captopril, pancytopenia, 401; captopril, tongue ulceration, 821; carbamazepine, congestive heart failure, 300; carbamazepine, granulomatous hepatitis, 1009; carbamazepine, pulmonary eosinophilia, 613; cardiovascular drugs, sexual dysfunction, 146; cefamandole, meningitis, 821; cephalothin, pancytopenia, 498; chlorambucil, acute leukemia, 498; chloramphenicol, aplastic anemia, 300; 2-chloroprocaine, no toxicity with high plasma levels, 498; chlorpromazine, lupus-like syndrome, 401; chlorzalinolone, impotence, 60; cimetidine, acute renal failure, 916; cimetidine, cardiac arrest, 401; cimetidine, depression, 222; cimetidine, hepatitis, 706; cimetidine, interstitial nephritis, 60; cimetidine, leukoclastic vasculitis, 1009; cimetidine, side effects, 300; cisplatin, hypertension, 401; clindamycin, pseudomembranous colitis, 498; clofibrate, acute renal failure, 300; coffee, pancreatic cancer, 498; danazol, hypertension, 146; dapsone, hypersensitivity reaction, 402; dapone, hyponatremia, 706; dementia, agents associated with, 613; diazepam, no risk of breast cancer, 821; dioxin, nightmares, 222; disopyramide, cardiovascular collapse, 821; disopyramide, hypoglycemia, 60, 300, 916; disulfiram, polyneuropathy, 916; diuretics, hyponatremia, 916; droperidol, acute dystonia, 1009; drugs associated with drug fever, 498; erythromycin, immune hemolysis, 706; flurazepam, cholestatic jaundice, 821; gentamicin, nephrotoxicity, 146; haloperidol, acute dystonic reaction, 60; halothane, renal failure, 613; halothane, renal and hepatic failure, 706; heparin, thrombotic thrombocytopenia, 613; hydroalazine, hepatotoxicity, 300; hydralazine, pancytopenia, 613; jaundice, 821; hydrochlorothiazide, triamterene, acute interstitial nephritis, 300; hydrocortisone, topical complications, 706; hydrogen peroxide, acute ulcerative colitis, 821; L-5-hydroxytryptophan/carbidopa, scleroderma-like illness, 60; iatrogenic disease at a university hospital, 500; ibuprofen, hyponatremia, 300; imipramine, withdrawal symptoms, 1009; indomethacin,

hyperkalemia, 62, 821; indomethacin, renal function deterioration, 916; interstitial nephritis, drug-induced, 222; intravenous fat emulsion, hypersensitivity reaction, 402; iodine, hyperthyroidism, 1009; levodopa, cardiac arrest, 500; licorice, hypokalemia, 146; lidocaine, fatal heart rate decelerations, 500; lithium, nephrotic syndrome, 613; lithium, neurological side effects 146; measles vaccine, thrombocytopenia, 1009; mephobarbital, hepatic necrosis, 402; methadone, choreic movements, 146; methyldopa, colitis, 710; methyldopa, systemic lupus-like syndrome, 916; methylprednisolone, sudden death, 1009; metronidazole, pseudomembranous colitis, 613; minocycline, pigmentation, 222; morphine, catatonias, 222; naloxone, cardiac arrest, 146; naproxen, bronchospasm, 300; neomycin, neuromuscular blockade, 613; oral contraceptives, endometrial cancer 146; oral contraceptives, myocardial infarction, 1009; oral contraceptives, systemic lupus erythematosus, 300; papaverine, abnormal liver function tests, 146; penicillamine, cholestatic jaundice, 710; pentamidine isethionate, acute pancreatitis, 402; phenylpropanolamine, CNS reactions, 402; phenylpropanolamine, psychotic episode, 146; prazosin, hypothermia, 222; propranolol, complete AV block, 500; propranolol, hypoglycemia, 146; propylthiouracil, hepatic disease, 62; psychotropic drugs, side effects, 146; pyridostigmine bromide, toxic alopecia, 222; quinine, acute toxic psychosis, 710; rabies vaccine, Guillain-Barre syndrome, 222; salicylates, Reye's syndrome, 300; smokeless tobacco, oral and pharyngeal cancer, 613; soft drink (Wink[®]), anaphylactic reaction, 62; sulfamethoxazole/trimethoprim, hepatic failure, 710; sulfapyrazole, acute renal failure, 613; sulindac, agranulocytosis, 821; sulindac, hepatitis, 500; sulindac, interstitial pneumonitis, 1009; sulindac, pancreatitis, 222; tamoxifen, hypercalcemia, 500; terbutaline, hypokalemia, 300; tetracycline, benign intracranial hypertension, 710; theophylline, depression, 222; theophylline, urinary retention, 500; thiazide diuretics, acute cholecystitis, 613; thioriental, anaphylaxis, 146; thyroid hormones, not associated with breast cancer, 62; timolol, congestive heart failure, 402; tobramycin, nephrotoxicity, 916; tolmetin, aseptic meningitis, 300; tolmetin, renal failure, 916; topical medications, allergic reactions, 62, total parenteral nutrition, decreased 1,25-dihydroxycholecalciferol, 821; triamterene, hyperpyrexia, 62; triamterene, nephrolithiasis, 916; trimethoprim/sulfamethoxazole, acute megaloblastic anemia, 916; trimethoprim/sulfamethoxazole, intrahepatic cholestasis, 1009; vaginal speculums, congenital malformations, 614; valproic acid, asterixis, 500; valproic acid, recurrent pancreatitis, 710; verapamil, hepatotoxicity, 710; vincristine, optic atrophy and blindness, 222; vitamin C, no adverse effects, 821; warfarin, cholestatic jaundice, 300; zomepirac, anaphylactic reaction, 710
Affirm, Melton B. (author) Failure of Rifampin to Induce the Metabolism of Clonidine in Normal Volunteers, 964
Aging see **Geriatrics**; White House conference, 715
Albumin, in pediatrics (CTF) 144
Alcohol, beneficial effects, 703; fetal alcohol syndrome, 545; in adverse drug reactions (CTF) 1009; report cites health hazards, 235
Alfalfa Seeds, pancytopenia, in adverse drug reactions (CTF), 613
Allaben, James W. (author) book review, 142
Allergic Extracts, withdrawal not contemplated, 509
Allopurinol, bullae associated with therapy, 490; in neurology (CTF) 497, 705; reversible flu-like syndrome, leukopenia, and thrombocytopenia, 286
1-Alpha-Acetylmethadol, in general medicine (CTF) 496
Alprazolam, adverse drug reactions, 636; dosage, 637; new drug evaluation, 633; pharmacokinetics, 634; side effects, 636
Aluminum Chloride Hexahydrate, in dermatology (CTF) 143
Aluminum Hydroxide, encephalopathy, in adverse reactions (CTF) 401; in renal disease (CTF) 145
Ambrose, Peter J. (author) letter, authors' reply, 810; (author) letter, lack of effect of cimetidine on theophylline clearance, 389
American Association of Colleges of Pharmacy, resolution, 714
American College of Clinical Pharmacy abstracts from

papers of second annual meeting, 476, index, 486; call for abstracts, 918; fall meeting, 931; highlights of second annual meeting, 729; letter of criticism, 391; midyear session, 918; second annual meeting, 247; Therapeutic Frontiers lectureship, 521
American Society of Consultant Pharmacists, survey, 714
Amikacin, comparative evaluation, 855; in ophthalmology (CTF) 221; in pediatrics (CTF) 705; penetration into synovial fluid, 284
Amiloride, new drug evaluation, 94; pharmacokinetics, 95
Amino Acids, in gastroenterology (CTF) 298; in intravenous therapy (CTF) 705
Aminocaproic Acid, myoglobinuria, in adverse drug reactions (CTF) 222
Aminoglutethimide, in oncology (CTF) 299
Aminoglycosides, comparative evaluation for systemic use, 847; predicting serum levels using a hand-held calculator, 751; synergistic nephrotoxicity with cephalosporin, 248
Aminophylline, in pediatrics (CTF) 299
4-Aminopyridine, in anesthesiology (CTF) 704; in intravenous therapy (CTF) 400
5-Aminosalicylic Acid, in gastroenterology (CTF) 1007
Amiodarone, in cardiovascular disease (CTF) 704
Amitriptyline, anxiety, in adverse drug reactions (CTF) 300; in geriatrics (CTF) 611; in neurology (CTF) 705, 820
Amoxapine, in psychiatry (CTF) 299, 401, 915
Amphotericin B, intraarticular, 884; in intravenous therapy (CTF) 612; pulmonary toxicity, in adverse drug reactions (CTF) 706; spinal cord damage, in adverse drug reactions (CTF) 60
Ampicillin in pediatrics (CTF) 59, 820; reversible neutropenia in pediatric patients, 802
Amygdalin, no toxicity observed, in adverse drug reactions (CTF) 401
Analgesics, gastric ulcers, in adverse drug reactions (CTF) 613; narcotic, toxic interaction with propranolol, 290; treatment of spine pain patients, 958
Anderson, Phillip O. (coauthor) see **Macfie, Helen L.**, 94; (coauthor) see **Masamori, Debra**, 278
Androgens, in renal disease (CTF) 613
Anesthetics (CTF), 4-aminopyridine, 704; bacterial filters, 818; bupivacaine, 704; dantrolene, 398; diazepam, 297, 913; enflurane, 1006; epinephrine, 913; fentanyl, 398, 704; hydralazine, 818; hydroxyzine, 818; intravenous agents, 495; ketamine, 219, 610; local anesthetics, 219; malignant hyperthermia, 219; methohexital, 297; morphine, 58, 610; muscle relaxants, 495; naloxone, 143; physostigmine, 143; sodium citrate, 495, 1006; trimethoprim, 820
Anderson, Richard C. (author) antibiotic-oral contraceptive interaction, 280; (contributing editor) DIAS Rounds, 278
Angaran, David (author) letter, the tenuring, 494
Antacids, hypermagnesemia, in adverse drug reactions (CTF) 498; in gastroenterology (CTF) 496; in general medicine (CTF) 914; lack of efficacy (ed) 120; osteomalacia, in adverse drug reactions (CTF) 300
Antibiotics, in infectious disease (CTF) 496; in obstetrics/gynecology (CTF) 612; penetration into cerebrospinal fluid, 341; table of CSF antimicrobial concentrations, 148; teratogenicity, 550
Anticoagulants, in cardiovascular disease (CTF) 220; teratogenicity, 551
Anticonvulsants, in neurology (CTF) 59; in obstetrics/gynecology (CTF) 59, 299, 1007; in pediatrics (CTF) 705; teratogenicity, 551
Antiemetics, delta-9-tetrahydrocannabinol, 867; teratogenicity, 555
Antidepressants, cardiovascular function, in adverse drug reactions (CTF) 706
Antidiabetic Agents, teratogenicity, 553
Antihypertensive Agents see individual agents
Antiinflammatory Agents, nonsteroidal, combination use, 3
Antineoplastic Agents, teratogenicity, 550
Antineoplastics, in oncology (CTF) 59
Antipsychotic Agents, in psychiatry (CTF) 498
Antipsychotic Agents, in psychiatry (CTF) 299; in the geriatric patient, 940; teratogenicity, 555
Antithrombotic Agents, in cardiovascular disease (CTF) 143
Antituberculars, teratogenicity, 550
Apnea, Neonatal, in pediatrics (CTF) 820
Appleby, Daryl H. (author) fenpropofen overdose, 129

Agrotis, in endocrinology (CTF) 1007

Archambault, George F. (ed) *The Compulsory Continuing Education Controversy*, 928; (ed) *In Defense of Eight Public Health Service Hospitals and Their 29 Satellite Clinics*, 624; (ed) *The Drug Lag in the U.S.*, 160; (ed) *A Job Well Done*, Dr. Goyan, 320; (ed) *Prescriber Problems with Potential and Unknown Drug Actions and Reactions*, 716; (ed) *Proposed Conditions of Participation*, 238; (ed) *A Time for Reflection about the FDA* — June 1981, 512; (ed) *The Two Standards for Pharmacy Services in Hospitals*, 78; (ed) *Using Supplemental Labels—A Matter of Judgment*, 1022; (ed) *USP DI — Supplying a Needed Service*, 831; (ed) *Violence Against Pharmacists — The Need for Federal Legislation*, 416; (ed) *Washington News and Comments*, 75, 156, 235, 317, 414, 508, 621, 713, 828, 925, 1020

Arrhythmias, Ventricular, use of N-acetylprocainamide, 398

Arthritis, combination use of antiinflammatory drugs, 3; mussel extract as treatment, 157; nongonococcal bacterial septic, treatment of, 531; septic, amikacin penetration into synovial fluid, 284; stercoral, treatment with moxalactam, 288

Ascorbic acid, in nutrition (CTF) 1007; in renal disease (CTF) 60

Aspartame, approved artificial sweetener, 925

Aspirin, bioavailability, comment on, 53; in adverse drug reactions (CTF) 916; hepatic encephalopathy, in adverse drug reactions (CTF) 60; in gastroenterology (CTF) 819; in general medicine (CTF) 298; in obstetrics/gynecology (CTF) 144; in pediatrics (CTF) 400; pharmacokinetic interactions, 4

Aspirin, Buffered, fecal blood loss, in adverse drug reactions (CTF) 1009

Association of Military Surgeons of the United States, annual meeting, 156

Asthma, allergic, carpet cleaning solution, 694; in obstetrics/gynecology (CTF) 299; influence of gender on theophylline dosage in children, 338

Atkins, Judy M. (author) letter, comment on PD designation, 810

Auranofin, in rheumatology (CTF) 145

Ausman, R.K. (author) Frozen Storage and Microwave Thawing of Parenteral Nutrition Solutions in Plastic Containers, 440

Aziz, Mohammed T. (coauthor) see Kumar, Ashir, 50

Azulidine, in gastroenterology (CTF) 298

B

Bacampicillin, in infectious disease (CTF) 611, 705

Bacitracin, in infectious disease (CTF) 143

Baclofen, in pediatrics (CTF) 915

Ballie, G.R. (author) flupenthixol poisoning in a child, 388; (author) letter, the effect of capsule color on hypnotic efficacy, 492

Barbeau, Gilles (coauthor) see Boisvert, Alain, 126

Barbiturates, pleurothorax occurring with neuro-resuscitations, 601

Barium Chloride, in toxicology (CTF) 1009

Barker, Kenneth N. (author) comment on medication administration article, author's reply, 136

Barletta, Michael (coauthor) see Pazzatti, John T., 492

Barriere, Steven L. (coauthor) see Honda, Dennis H., 284

Barton, David F. (author) more on lorazepam withdrawal, 134

Batenhorst, Randal L. (author) book review, 393

Bauman, Jay H. (author) letter, comment on effect of cimetidine on theophylline clearance, 808

Bauman, Jerry (coauthor) see Lee, Mary, 782

Baumgartner, Thomas G. (author) comment on neuro-emulsion compatibility, 908

Bayliff, C.D. (author) electrolyte abnormalities following povidone-iodine therapy, 801

BCC, in urology (CTF) 916

BCNU, in oncology (CTF) 612

Beck, Diane E. (author) toxicities with intravenous and subcutaneous administration of a petroleum distillate, 693

Beclomethasone Dipropionate, in pulmonary disease (CTF) 145

Begebe, Claudia (coauthor) see Salem, Ronald B., 992

Behavior, methods of modifying compliance in hypertensive patients, 8

Bendectin, in obstetrics/gynecology (CTF) 915; new labeling, 828

Bendroflumethiazide, in renal disease (CTF) 1008; in urology (CTF) 916

Benazepril, in neurology (CTF) 914

Benzydiazepines, in toxicology (CTF) 821

Berg, Mary J. (author) Cimetidine in Systemic Mastocytosis, 180

Berman, Alex (author) book review, 702

Bernhard, Harold (coauthor) see Berg, Mary J., 180

Betamethasone, in pediatrics (CTF) 49

Bethanechol, in gastroenterology (CTF) 220; in urology (CTF) 145

Bickett II, William J. (coauthor) see Sawyer, William T., 53

Birth Defects, restrictions on test kit, 157

Bithionol, treatment of parasites, 104

Black, Curtis D. (author) authors' reply to letter, 909; (author) *A Study of Intravenous Emulsion Compatibility: Effects of Dextrose, Amino Acids, and Selected Electrolytes*, 184

Bleomycin, in oncology (CTF) 299; in adverse drug reactions (CTF) 22

Bloch, Richard (coauthor) letter, authors' reply, 697; (coauthor) see Mannion, James C., 248

Bloom, Michael G. (author) letter, non-estrogen treatment for menopausal symptoms, 132

Boisvert, Alain (author) book review, 218, 911; (author)

nalidixic acid-induced photodermatitis after minimal sun exposure, 126

Books Received, 912

(American Medical Association) 830; *Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology* (R. C. Baselt) 139; *Anatomy, Physiology, Pathophysiology of Man. A Textbook for Pharmacists and Biologists* (G. Thews et al.) 296; *Antibiotics and Chemotherapy, Current Topics* (R.N. Gruneberg) 295; *Antifungal Chemotherapy* (D.C.E. Speller) 217; *Clinical Pharmacological Evaluation in Drug Control* (World Health Organization) 392; *Concepts in Drug Metabolism* — Part A (P. Jenner, B. Teste) 815; *Critical Care — State of the Art* (W.C. Shoemaker, W. L. Thompson) 395; *Current Developments in Psychopharmacology*, Vol. 5 (W.B. Essman, L. Valzelli) 138; *Drugs and the Elderly: Perspective in Geriatric Clinical Pharmacology* (J. Crooks) 911; *Elsevier's Dictionary of Pharmaceutical Science and Techniques*, Volume 2: *Materia Medica* (A. Sliossberg) 701; *Enteral Hyperalimentation with Chemically Defined Elemental Diets: A Source Book*, 2nd ed. (D.B. Worthen, J.R. Lorimer) 140; *Handbook of Basic Pharmacokinetics*, 2nd ed. (W.A. Ritschel) 393; *Handbook of Essential Drug Therapy for Critical Care Nurses* (J. Romankiewicz et al.) 816; *Index Guide to Drug Information Retrieval* (H. Fukushima, T. Okazaki, M. Noguchi) 141; *Mathematics for Health Occupations* (D. Bila et al.) 142; *Medication Teaching Manual: A Guide for Patient Counseling*, 2nd ed. (ASHP) 137; *Meyler's Side Effects of Drugs*, 9th ed. (M.N.G. Dukes) 701; *National Health Insurance — Conflicting Goals and Policy Choices* (J. Feder et al.) 702; *Nurses' Guide to Drugs 1980* (Nursing 80 Books) 295; *Nutrition and Cancer: Proceedings of the 18th Annual Meeting of the American College of Nutrition* (J.V. Eys, M.S. Sellig, B.L. Nicholas) 141; *Pediatric Dosage Handbook* (H.C. Shirley) 816; *Pharmacy: A Profession in Search of a Role* (J. Robbins) 817; *Practical Clinical Psychopharmacology* (W.S. Appleton) 911; *Practical Guide to Geriatric Medicine* (R.J. Burant) 217; *Practical Pharmacology — for Prescribers* (J.R. DePalma) 137; *Preparing a Drug Abuse Workforce: A National Training System* (C. Davis, L.C. Ford) 394; *Principles and Practice of Infectious Disease* (G.L. Mandell et al.) 396; *Problems in Pediatric Drug Therapy* (J.A. Pagliaro, R.H. Levin) 139; *Progress in Clinical Pharmacy II* (G. Aulanger) 911; *Progress in Drug Research* (E. Jucker) 701; *Psychopharmacology of Aggression* (M. Sandler) 394; *The Selection of Essential Drugs* (WHO) 218; *Selective Toxicity*, 5th ed. (A. Albert) 218; *Side Effects of Drugs Annual 4* (M.N.G. Dukes) 141; *USAN and the USP Dictionary of Drug Names 1981* (M.C. Griffiths) 137; *USP XX-NF XV* (USP) 140; *UV and IR Spectra of Some Important Drugs* (H.W. Dibbern) 142

Bosso, John A. (author) book review, 139

Brack, Graham (author) letter, *British National Formulary* and child-resistant containers, 604; (author) letter, *European Economic Community and pharmacy practice*, comment, 810; (author) letter, the rise and fall of notional pricing, 392

Bradberry, J. Chris (author) *Continuous Infusion of Naloxone in the Treatment of Narcotic Overdose*, 945

Bradley, Wayne E. (coauthor) see Straz, Marc H., 838

Breast Feeding, in pediatrics (CTF), 1008

Bretlyum Tostyle, in cardiovascular disease (CTF) 1007; in intravenous therapy (CTF) 400; in toxicology (CTF) 222

British National Formulary, child-resistant containers, 604

Bromeripine, in endocrinology (CTF) 143, 819; salicylates and hypotension in cardiovascular disease, in adverse reactions (CTF) 60; in obstetrics/gynecology (CTF) 612, 705

Brook, Robert H. (coauthor) see Lohr, Kathleen N., 758

Broosda, Andrea (author) *pharmacy-nursing Kardex* rounds — a communication technique, 216

Bryant, Stephen G. (author) *Determinants of Compliance in Epileptic Outpatients*, 572

Bupivacaine, in anesthesiology (CTF) 704

Burke, Wayne S. (author) *Comparative Evaluation of the Aminoglycoside Antibiotics for Systemic Use*, 847

Burmeister, Leon F. (coauthor) see Helling, Dennis K., 581; (coauthor) see Norwood, G. Joseph, 656

Burner, David E. (coauthor) see Robinson, J. Daniel, 49

Busch, Douglas A. (coauthor) see Prince, Randall A., 372

Butriptyline, in general medicine (CTF) 819

C

Cady, William J. (coauthor) see Rehder, Terry L., 205

Caffeine, fibrocystic breast disease, 925; fluid and electrolyte imbalance, in adverse drug reactions (CTF) 60

Calcitonin, in endocrinology (CTF) 399

Calcium, antagonism in cardiovascular disease (CTF) 297

Calcium Gluconate, in toxicology (CTF) 616; mania, in adverse reactions (CTF) 60

Caldwell, E. Gerald (coauthor) see McGraw, Benjamin F., 578

Calvert Jon C. (coauthor) see Longe, R. Leon, 166

Campbell, R. Keith (author) *The Treatment of Narcolepsy and Cataplexy*, 247

Campbell, William H. (author) *Issues and Priorities for Research in Geriatric Pharmaceutical Care*, 111

Camphorated Oil, removal from market recommended, 158

Cancer, in adverse drug reactions (CTF) 613

Cantharidin, in toxicology (CTF) 706

Cantwell, R. (coauthor) see Ausman, R.K., 440

Capitation, effects of payment for pharmacy services on pharmacist-dispensing and physician prescribing, 656

Capmul 8210, in gastroenterology (CTF) 611

Captopril, hepatocellular jaundice, in adverse drug

reactions (CTF) 706; in cardiovascular disease (CTF) 297, 398; in obstetrics/gynecology (CTF) 705; nephrotic syndrome, in adverse drug reactions (CTF) 146; new drug evaluation, 932; pancytopenia, in adverse drug reactions (CTF) 401; tongue ulceration, in adverse drug reactions (CTF) 821

Carbamazepine, congestive heart failure, in adverse drug reactions (CTF) 300; eosinophilia, in adverse drug reactions (CTF) 613; granulomatous hepatitis, in adverse drug reactions (CTF) 1009; in neurology (CTF) 144; in psychiatry (CTF) 706

Cardioids, scleroderma-like illness, in adverse drug reactions (CTF) 60

Cardiologists, first annual report, 75

Cardiovascular Disease (CTF), aceclofenadine, 58; N-acetylprocainamide, 1006; amiodarone, 704; antithrombotic agents, 143; bretylium tosylate, 1007; calcium antagonists, 297; captopril, 297, 398; colestipol/nicotinic acid, 496; digoxin, 219; diltiazem, 610, 1007; dipyrindamole, 297; disopyramide, 58, 219, 398, 496; diuretics, 496; dobutamine, 58, 219, 297; electrocardiogram, 1007; enalapril, 1007; guanadrel, 704; heparin, 610; intravenous nitroglycerin, 704; lorazepam, 143; metoprolol, 219; mexiletine, 704; minoxidil, 143, 219; nifedipine, 704, 914; nitroglycerin, 704; nitroglycerin, 297, 610; oral anticoagulants, 220; orthostatic hypotension, 143; pindolol, 611; prazosin, 143, 297, 914; procainamide/quinidine, 611; propranolol, 58; streptokinase, 914; timolol, 611; verapamil, 399, 611, 914; xipamide, 220

Cardoni, Alex A. (coeditor) *New Drug Evaluations*, 94, 325, 425, 522, 633, 838, 932

Caruthers-Czyzewski, Patricia (author) book review, 141

Case Reports, acute ethylene oxide intoxication, 384; acute stomatitis associated with dextrophen therapy, 992; amikacin penetration into synovial fluid during treatment of septic arthritis, 284; bullae associated with allopurinol, 490; the case of the clean rug, 694; electrolyte abnormalities following povidone-iodine topical therapy, 801; elevated serum phenytoin concentrations in a uremic patient when measured by enzyme-multiplex immunoassay, 386; elevations in serum transaminases and alkaline phosphatase secondary to papaverine hydrochloride, 127; fenopropfen overdose, 129; flupenthixol poisoning in a child, 388; hyperglycemia associated with propranolol and chlorpromazine coadministration, 599; hypertensive crisis resulting from avocado and a MAO inhibitor, 904; hypoprothrombinemia associated with moxalactam treatment of stercoral arthritis, 288; methylodopa-induced hemolytic anemia and parkinsonism, 704; moxalactam in treatment of recurrent *E. coli* meningitis and trichuriasis in an infant with agammaglobulinemia, 50; nalidixic acid-induced photodermatitis, 126; nitrates in the treatment of diffuse esophageal spasm, 806; oxazepam withdrawal convulsions, 487; penicillin G-induced granulocytopenia, 289; pleurothorax as a complication of barbiturate-induced coma for neuro-resuscitation, 601; *Pneumocystis carinii* pneumonia, 734; propranolol plasma concentrations and pharmacokinetics, 993; psychiatric complications with erythromycin, 388; psychotic exacerbation with haloperidol, 209; retroperitoneal fibrosis after treatment with propranolol, 696; reversible flu-like syndrome, leukopenia, and thrombocytopenia induced by allopurinol, 286; reversible neutropenia associated with ampicillin therapy in pediatric patients, 802; severe diarrhea secondary to propranolol, 49; severe lithium poisoning, 598; severe tracheobronchitis from inhalation of isobutyl nitrite preparation, 51; toxicities with intravenous and subcutaneous administration of a petroleum distillate, 693; unusual presentation for a urinary tract infection, 904; urinary hesitancy with L-tryptophan, 996; use of colestipol in a patient with digoxin intoxication, 902

Cassel, Deborah H. (coauthor) see Prince, Randall A., 863

Cataplexy, treatment, 257

Catastrax, association with drugs and chemicals, 434

Cato, Allen E. (coauthor) see Cocchetto, David M., 867

CCNU, in oncology (CTF) 497

Cefaclor, in infectious diseases (CTF) 59, 105; in pediatrics, (CTF) 1008

Cefadroxil, in infectious diseases (CTF) 220; in pediatrics (CTF) 915

Cefamandole, bad taste, 136; in infectious disease (CTF) 496; in obstetrics/gynecology (CTF) 299; meningitis, in adverse drug reactions (CTF) 821; treatment of soft tissue and skeletal infections, 951

Cefazolin, in infectious disease (CTF) 705

Cefotaxime, in infectious disease (CTF) 914

Cefoxitin, in infectious disease (CTF) 298

Cefuroxime, in infectious disease (CTF) 399

Cephalexin, in infectious disease (CTF) 611

Cephadrine, treatment of actinomycosis, 101

Cephazolin, aminoglycoside synergistic nephrotoxicity, 248

Cephalothin, pancytopenia, in adverse reactions (CTF) 498; treatment of actinomycosis, 101

Cerebrospinal Fluid, antineoplastic penetration, 341

Chambers, Richard A. (author) letter, comment on parasitic diseases, author's reply, 390

Charcoal, Activated, in renal disease (CTF) 60

Chemotherapy, potentiation of myelosuppression with thiazides, 967

Chenodiol, treatment of gallstones, 610

Cherniak, Gail (author) *Counseling the Hearing-Impaired Older Adult*, 377

China, People's Republic of, impression of a pharmaceutical scientist, 674

Chloral Hydrate, in geriatrics (CTF) 298

Chlorambucil, acute leukemia, in adverse drug reactions (CTF) 498

Chloramphenicol, in infectious disease (CTF) 819; in pediatrics (CTF) 59, 145, 497, 820; treatment of actinomycosis, 101

Chlordiazepoxide, teratogenicity, 556

2-Chloroprocaine, no toxicity reported, in adverse reactions (CTF) 498

Chloroquine Hydrochloride, treatment of parasites, 104

Chloroquine Phosphate, treatment of *Entamoeba histolytica*, 109

Chlorpheniramine Maleate, in general medicine (CTF) 496

Chlorpromazine, lupus-like syndrome, in adverse reactions (CTF) 401

Chlorpromazine, in endocrinology (CTF) 298;

hyperglycemia, 599; teratogenicity, 554

Chlorthalidone, inotension, in adverse drug reactions (CTF) 60; in pregnancy, 22

Cholestyramine, in dermatology (CTF) 399; in toxicology (CTF) 706

Choline, in hematology (CTF) 704; in neurology (CTF) 298, 820

Cimetidine, acute renal failure, in adverse drug reactions (CTF) 916; allograft rejection, 278; for systemic mastocytosis, 180; cardiac arrest, in adverse drug reactions (CTF) 401; depression, in adverse drug reactions (CTF) 222; in dermatology (CTF) 220, 914; in gastroenterology (CTF) 58, 220; in intravenous therapy (CTF) 820; in ophthalmology (CTF) 497; in renal disease (CTF) 145, 401; interstitial nephritis, in adverse drug reactions (CTF) 60; lack of effect on theophylline clearance, 389; leukoclastic vasculitis, in adverse drug reactions (CTF) 1009; predicting drug interactions, 495; side effects, in adverse drug reactions (CTF) 300; sinus bradycardia, 492

Cinoxacin, in infectious disease (CTF) 59, 1007

Cisneros, Robert M. (coauthor) see **Zelino, Robert N.** 292

Cisplatin, hypertension, in adverse drug reactions (CTF) 401; in oncology (CTF) 612, 820, 1008

Citrobacter Diversus, septic sternoclavicular arthritis, treatment with moxalactam, 288

Clindamycin, in dermatology (CTF) 58, 143, 1007; pseudomembranous colitis, in adverse drug reactions (CTF) 498; treatment of actinomycosis, 101

Clinical Pharmacy, evaluation of programs, 459; quality assurance, 758; recognition of, 267

Clofazimine, in dermatology (CTF) 611

Clofibrate, acute renal failure, in adverse drug reactions (CTF) 300

Clofibrate, in obstetrics/gynecology (CTF) 612, 705

Clofibrate, failure to interact with rifampin, 964; in ophthalmology (CTF) 1008; in pregnancy, 24; in psychiatry (CTF) 401; in toxicology (CTF) 401

Clofibrate, in infectious disease (CTF) 221; in rheumatology (CTF) 221

Co-Trimoxazole, in oncology (CTF) 705

Cochetto, David M. (author) A Critical Review of the Safety and Antiemetic Efficacy of Delta-9-tetrahydrocannabinol, 867

Codine, in gastroenterology (CTF) 298

Coffee, pancreatic cancer, in adverse drug reactions (CTF) 498

Cohen, Ian J. (author) psychiatric complications with erythromycin, 388

Colchicine, in dermatology (CTF) 297; in rheumatology (CTF) 60, 613

Coleman, James H. (author) Rational Use of Psychoactive Drugs in the Geriatric Patient, 940

Colistipol, in cardiovascular disease (CTF) 496; for digoxin intoxication, 902

Collagenase, in neurology (CTF) 497

Color Additives, testing deadline delayed, 158

Colvin, Carol L. (coauthor) **Macfie, Helen L.** 94

Compliance, community pharmacists and patient package inserts, 117; determinants in epileptic outpatients, 572; methods of modifying behavior in hypertensive patients, 8

Conner, Christopher S. (editor) Current Therapeutic Findings, 58, 143, 219, 296, 398, 495, 610, 703, 818, 913, 1006

Conrad, Kathy (author) letter, controlling nausea and vomiting in pregnancy, 1002

Contact Lens, salt tablet kit approved, 76

Contraception, in pediatrics (CTF) 1008

Cook, Linda F. (coauthor) see **Cochetto, David M.**, 867

Corrections, 700, 1002

Corticosteroids, in neurology (CTF) 497

Cortisol in obstetrics/gynecology (CTF) 221

Cortisporin, otic solution versus suspension, 278

Covalla, John R. (author) severe tracheobronchitis from inhalation of an isobutyl nitrite preparation, 51

Covinsky, Joel O. (author) book review, 137

Creatinine Clearance, influence of urine flow, 194

Cromolyn Sodium, in gastroenterology (CTF) 399, 704; in pediatrics (CTF) 145

Croust, Richard J. (author) The Drug Regulatory System: Reflections and Predictions, 793

Cryoprecipitate, in renal disease (CTF) 221

Current Therapeutic Findings, 58, 143, 219, 296, 398, 495, 610, 703, 818, 913, 1006

Cyanide, in toxicology (CTF) 1009

Cyclophosphamide, in rheumatology (CTF) 60

Cyr, Dale A. (coauthor) see **Kaul, Alan F.**, 981

Cytarabine, in oncology (CTF) 144

D

Dalín, Gary L. (author) letter, comment on an independent national organization for pharmacy technicians, 699

Danzol, hypertension, in adverse drug reactions (CTF) 58; in dermatology (CTF) 297; in general medicine (CTF) 58; in pediatrics (CTF) 820

Dantrolene, in anesthesiology (CTF) 398

Dapsone, hypersensitivity reaction, in adverse drug reactions (CTF) 402; hypalbuminemia, in adverse drug reactions (CTF) 706; in rheumatology (CTF) 1008

Dasta, Joseph F. (author) book review, 395

Davis, Larry J. (coauthor) see **Andersen, Richard C.**, 280; (coauthor) see **Yen, Linda R.**, 885; (editor) DIAS Rounds, 278, 884

Davis, W. Marvin (author) possible toxic interaction of propranolol and narcotic analgesics, 290

Deanol, in psychiatry (CTF) 1008

Debes-Joy, in obstetrics/gynecology (CTF) 1008

Deferoxamine, in renal disease (CTF) 60

Dehydroemetine, treatment of parasites, 104

Delta-9-Tetrahydrocannabinol, critical review of safety and antiemetic efficacy, 867; in oncology (CTF) 705, 820

Dementia, in adverse drug reactions (CTF) 613

Department of Health and Human Services, new commissioner, 508; war on waste, 508

Deprenyl, in neurology (CTF) 497

Dermatology (CTF), aluminum chloride hexahydrate, 143; cholestyramine, 399; cimetidine, 220, 914; clindamycin, 58, 143, 1007; clofazimine, 611; colchicine, 297; danazol, 297; dermatophytosis, 399; ketoconazole, 496; lupus erythematosus, 611; naloxone, 704; peritoneal dialysis, 496; phenytoin, 58; polymyositis vaccine, 297; potassium iodine, 399; retinoids, 297, 704; Selsun Blue Shampoo, 914; terbutaline, 143; triamcinolone acetonide, 914; zinc sulfate, 220

Dermatophytosis, in dermatology (CTF) 399

DeNicola, Lucian K. (author) phlebotomy as a complication of barbiturate-induced coma for neuroresuscitation, 601

Desipramine, plasma concentration monitoring of hydroxylated metabolites, 263

DeVane, C. Lindsay (author) Plasma Concentration Monitoring of Hydroxylated Metabolites of Imipramine and Desipramine, 263

Diabetes, urine testing in South Carolina, 292; glycosylated hemoglobins and diabetic control assessment, 175

Dialysis, cost effective reimbursement, 75; vancomycin pharmacokinetics, 15

Diarrhea, with propranolol, 49

DIAS Rounds, 278, 884

Diazepam, breast cancer risk, in adverse drug reactions (CTF) 821; in anesthesiology (CTF) 297, 913; in intravenous therapy (CTF) 59, 400; teratogenicity, 556

Diclofenac Sodium, absorption with aspirin, 4

Diethylstilbestrol, court rules on liability of manufacturers, 156; FDA update, 622; in obstetrics/gynecology (CTF) 497

Digitoxin, in geriatrics (CTF) 704

Digoxin, colestipol for intoxication, 902; in cardiovascular disease (CTF) 219; in obstetrics/gynecology (CTF) 820; nightmares, in adverse drug reactions (CTF) 222

Dihydroxyquin, treatment of *Entamoeba histolytica*, 109

Diloxanide Furoate, treatment of parasites, 104

Diltiazem, in cardiovascular disease (CTF) 610, 1007

Dimethylsulfoxide, adverse drug reactions, 415; FDA seizure of, 925; use for scleroderma, 1020

Dinitrochlorobenzene, in obstetrics/gynecology (CTF) 1008

Dipyridamole, in cardiovascular disease (CTF) 297, 819; in obstetrics/gynecology (CTF) 144

Dipyrene, in general medicine (CTF) 143

Disopyramide, hypoglycemia, in adverse drug reactions (CTF) 60, 300, 916; in cardiovascular disease (CTF) 58, 219, 398, 496; no development of ANA, in adverse drug reactions (CTF) 821

Disulfiram, polyneuropathy, in adverse drug reactions (CTF) 916

Diuretics, see individual agents; hyponatremia, in adverse drug reactions (CTF) 916; in cardiovascular disease (CTF) 496

Dobutamine, in cardiovascular disease (CTF) 58, 219, 297

Doecker, William J. (author) the case of the clean rug, 694; (coauthor) see **Kinsella, J.M.**, 603

Dopamine, in renal disease (CTF) 145

Dorevitch, Abraham P. (coauthor) see **Coleman, James H.**, 940

Doxepin, acute stomatitis, 992

Doxorubicin, in oncology (CTF) 400, 497

Doxycycline, in infectious disease (CTF) 1007; treatment of actinomycosis, 101

Draize Test, update, 318

Droperidol, acute dystonia, in adverse drug reactions (CTF) 1009

Drug Abuse, tracheobronchitis with inhalation of isobutyl nitrite, 51

Drug Fever, in adverse drug reactions (CTF) 498

Drug Information, New Jersey Medicaid provides consumer book, Jan-ctr 1; services activity, a citation analysis, 272

Drug Interactions (CTF)

- alcohol-cefamandole, 300
- alcohol-metronidazole, 843
- allopurinol-theophylline, 614
- allopurinol-vidarabine, 500
- antihypertensive agents-indomethacin, 62
- aspirin-indomethacin, 3
- aspirin-metronidazole, 843
- aspirin-phenytoin, 402
- beta-blocking agents-nifedipine, 222
- carbamazepine-cimetidine, 710
- carbamazepine-etoximide, 222
- carbamazepine-warfarin, 500
- carbenicillin/ticarcillin-gentamicin, 300
- cefamandole-alcohol, 300
- cimetidine-carbamazepine, 710
- cimetidine-lorazepam/oxazepam, 222
- cimetidine-phenytoin, 821, 1009
- cimetidine-propranolol, 402, 916
- cimetidine-tetracycline, 62
- cimetidine-theophylline, 916, 1009
- diffusional-warfarin, 146
- digoxin-quinidine, 62, 222, 402
- digoxin-disopyramide, 222
- digoxin-methyldopa, 614
- digoxin-nifedipine, 710
- digoxin-quinidine, 1009
- digoxin-quinine, 1009
- digoxin-rifampin, 222
- disopyramide-digoxin, 222

disulfiram-methadone, 146

diphenyl-probenecid, 614

ethoximide-carbamazepine, 222

food-warfarin, 614

furosemide-indomethacin, 146

gentamicin-carbenicillin/ticarcillin, 300

indomethacin-antihypertensive agents, 62

indomethacin-furosemide, 146

influenza vaccine-theophylline, 62

lidocaine-propranolol, 821

lorazepam/oxazepam-cimetidine, 222

methadone-disulfiram, 146

methadone-phenytoin, 614

methotrexate-trimethoprim, 62

methyldopa-digoxin, 614

methyldopa-phenoxymethamine, 500

methylprednisolone-troleandomycin, 300

metronidazole-alcohol, 843

metronidazole-aspirin, 843

nylanta-naproxen, 916

naproxen-mylanta, 916

nifedipine-beta-blocking agents, 222

nifedipine-digoxin, 710

phenoxymethamine-methyldopa, 500

phenytoin-aspirin, 402

phenytoin-cimetidine, 821, 1009

phenytoin-clonazepam, 62

phenytoin-methadone, 614

probenecid-diphenyl, 614

propranolol-cimetidine, 402, 916

propranolol-lidocaine, 821

quinidine-digoxin, 62, 222, 402

quinidine-digoxin, 1009

quinidine-rifampin, 821

quinine-digoxin, 1009

rifampin-digoxin, 222

rifampin-quinidine, 821

sulfapyrazole-warfarin, 710

tetracycline-cimetidine, 62

theophylline-allopurinol, 614

theophylline-cimetidine, 916, 1009

trimethoprim-methotrexate, 62

troleandomycin-methylprednisolone, 300

vidarabine-allopurinol, 500

vitamin K-warfarin, 402

warfarin-carbamazepine, 500

warfarin-diflunisal, 146

warfarin-food, 614

warfarin-sulfapyrazole, 710

warfarin-vitamin K, 402

warfarin-wine, 614

wine-warfarin, 614

Drug Lag, FDA status report, 319

Drug Regulation, industry's response, 799; reflections and predictions, 793

Drug Stability, frozen storage and microwave thawing of parenteral nutrition solutions in plastic containers, 440; meclofenoxate in parenteral admixtures, 331

Drug Therapy, pharmacist as prescriber, 665; psychoactive drugs in the geriatric patient, 940

Drug Utilization Review, rational use for internal standards, 789

Duncan, Douglas B. (coauthor) see **Talbert, Robert L.**, 993

Dunedin Program, epidemiology of serum potassium levels in the elderly, 467

E

Editorials

George F. Archambault, The Compulsory Continuing Education Controversy, 928; The Drug Lag in the U.S., 160; In Defense of Eight Public Health Service Hospitals and Their 29 Satellite Clinics, 624; A Job Well Done, Dr. Goyan, 320; Prescriber Problems with Potential and Unknown Drug Actions and Reactions, 716; Proposed Conditions of Participation, 238; The Two Standards for Pharmacy Services in Hospitals, 78; A Time for Reflection about the FDA—June 1981, 512; Using Supplemental Labels—A Matter of Judgment, 1022; USP DI—Supplying a Needed Service, 831; Violence Against Pharmacists—The Need for Federal Legislation, 416

Donald E. Francke, Physical Assessment and the Clinical Pharmacist, 208

Paul A. Kramer, Clinical Pharmacokinetics versus Therapeutic Drug Monitoring—A Perspective for Pharmacists, 474

Peter P. Lamy, 1981—The Year of the White House Conference on Aging, 383

Gerhard Levy, Accreditation Standards for Doctor of Pharmacy Programs, 470

William N. McLean, An Omen for Future Clinical and Administrative Managers, 900

Don C. McLeod, Pharm.D. Accreditation Standards, 472; The Legacy of Donald E. Francke: DPCP—A Fifteen-Year Commitment to Clinical Pharmacy, 990

Wayne L. Pines, 75 Years of FDA History, 512

Craig K. Svenson, Lack of Efficacy of Antacid Tablets—Fact or Fiction?, 120

Harvey A.K. Whitney, Jr., Pharmacy Technicians Establish an Independent National Organization, 281; The Legacy of Donald E. Francke: DPCP—A Fifteen-Year Commitment to Clinical Pharmacy, 990

Edmunds, Marilyn W. (author) book review, 816

Education, inservice, effect on nurses in long-term care facilities, 777

Edwards, S. Albert (coauthor) see **Rehder, Terry L.**, 205

Einarson, Thomas R. (author) letter, comment on lorazepam withdrawal, 133; (author) oxazepam withdrawal convulsions, 487

Electrocardiogram, in cardiovascular disease (CTF) 1007

Elmhurst, Julia (coauthor) see **Adams, Michael P.**, 280

Encainide, in cardiovascular disease (CTF) 1007

Endocarditis, in infectious disease (CTF) 221
Endocrinology (CTF), aprotinin, 1007; bromocriptine, 143; calcitonin, 399; chlorpromazine, 498; furosemide, 399; naloxone, 704; prednisone, 86; propranolol, 704; spirinolactone, 58; somatostatin, 611; sulfonylureas, 496
Enflurane, in anesthesiology (CTF) 1006
Epilepsy, determinants of compliance in epileptic outpatients, 572
Epinephrine, in anesthesiology (CTF) 913; in ophthalmology (CTF) 400; in pulmonary disease (CTF) 915
Ereshfsky, Larry (author) book review, 138; (coauthor) see Bryant, Stephen G., 572
Ericson, Avis J. (coauthor) see Rehder, Terry L., 205
Erick, Jeffrey Keith (author) letter, correction to erythromycin ototoxicity, 133
Erythromycin, clinical trial in inflammatory acne, 372; immune hemolysis, in adverse drug reactions (CTF) 706; psychiatric complications, 388; treatment of acromycosis, 101
Esophagus, nitrates for spasms, 806
Esipen-ingroff, A. (coauthor) see Polk, Ron E., 15
Estramustine, in oncology (CTF) 915
Estrogens, in obstetrics/gynecology (CTF) 144; in oncology (CTF) 144
Ethacrynic acid, in pregnancy, 22
Ethics, Pharmacy, "Bill of Rights" for pharmacists, 390
Ethinyl Estradiol, in obstetrics/gynecology (CTF) 59
Etoposide, in oncology (CTF) 144
Ethylene Oxide, acute intoxication, 384
Evans, R. Lee (author) Alprazolam, 633
Evans, William E., ACCP news, 93

F

Federal Food and Drug Administration, budget for 1982, 414, 509; fake pep pills, 713; improvement in new drug procedure, 622; injunction against Premo, 415; man in the plant problem, 508; major policy decisions, 622; national drug code directory, 714; radioactivity on ceramic dishes, 714; status for paper NDAs, 713; update on color additives, 622; update on diethylstilbestrol, 622
Feldick, Harley G. (coauthor) see Prince, Randall A., 372, 863
Feldman, Marvin J. (author) letter, use of a hand-held programmable calculator in performing neonatal parenteral nutrition solution calculations, 54
Fellowships and Residencies, 67, 147, 223, 302, 403, 822, 917, 1013
Fellowships and Residencies, Brigham and Women's Hospital, 822, 917; the Brookdale Hospital Medical Center, 223; Hartford Hospital, 223, 403; Medical University of South Carolina, 148, 917; Northeastern University, 917; The Ohio State University, 148, 302, 822, 918; Philadelphia College of Pharmacy and Science, 223; Saint Paul-Marshall Medical Center, 223, 303; University of Cincinnati, 67, 223; University of Florida, 147, 223; University of Illinois Hospital, 67, 223, 1013; University of Iowa, 403; University of Minnesota, 67, 147, 302; University of Missouri, 147, 223, 1013; University of Nebraska, 147, 917; University of North Carolina School of Pharmacy, 1014; University of Pittsburgh, 917; University of Southern California, 1014; University of Tennessee, 67, 148, 223; University of Texas, 70; University of Utah, 302, 403; University of Washington, 70, 148, 403; VA Medical Center with the University of Iowa, 302
Fenoprofen, overdose, 129; pharmacokinetic interactions, 4
Fentanyl, in anesthesiology (CTF) 398, 704
Fields, Ellen D. (author) book review, 911
Filters, Bacterial, in anesthesiology (CTF) 818
Fink, Arlene (author) Evaluating Clinical Programs: Methodological Guidelines, 536; (coauthor) see Koseoff, Jacqueline, 986
Finkelstein, Burt W. (author) Ritodrine, 425
Fischer, Richard G. (coauthor) see Salem, Ronald B., 992
Fish, Kenneth H. (author) book review, 817
Fisher, Wayne P. (coauthor) see Helling, Dennis K., 581; (coauthor) see Norwood, G. Joseph, 656
Flucytosine, in infectious disease (CTF) 59
Flunisolide, in pulmonary disease (CTF) 221
Fluorescent Lamps, ultraviolet radiation hazard, 510
5-Fluorouracil, in oncology (CTF) 144, 400, 915
Fluoro-DA, in renal disease (CTF) 145
Flupenthixol, poisoning in a child, 388
Flurazepam, cholestatic jaundice, in adverse drug reactions (CTF) 821
Flurbiprofen, inflammation studies, 5; in rheumatology (CTF) 299
Fong, Christine (coauthor) see Yen, Linda R., 885
The Food and Drug Law Institute, annual education conference held, 235; annual meeting, 926
Formic Acid, in toxicology (CTF) 401
Formulary, prescribing restrictions, reactions, 594
Foster, Mark S. (author) letter, comment on the tenuring, 909; (author) letter, "Doc Adams vs. 'dig' levels", 391
Frail, Dawn M. (author) book review, 701
Frankie, Donald E. (ed) Physical Assessment and the Clinical Pharmacist, 208
Fraser, Gilles L. (author) Treatment of Nongonococcal Bacterial Septic Arthritis, 531
Freeman, Betsy (coauthor) see Beck, Diane E., 693
Friesen, W.T. (author) Trimethoprim: Clinical Use and Pharmacokinetics, 325; (coauthor) see Vree, T.B., 194
Fujita, Toshio (coauthor) see Koshiro, Akira, 331
Furazolidone, in pediatrics (CTF) 497
Furosemide, in endocrinology (CTF) 399; in pregnancy, 22

G

Gans, John A. (coauthor) see Tannenbaum, Renee P., 766
Garrett, Edward R. (author) letter, comment on aspirin bioavailability monitoring, author's reply, 291
Gaskins, John D. (coauthor) see Holt, Robert J., 599;

(coauthor) see Postelnick, Michael, 289
Gasoline, in toxicology (CTF) 222
Gastroenterology (CTF), amino acids, 298; 5-aminosalicylic acid, 1007; antacids, 496; bethanechol, 220; capmul 8210, 611; cimetidine, 58, 220; codeine, 298; cromolyn sodium, 399, 704; glucagon, 399; hyoscine butylbromide, 704; insulin, 914; lactose, 1007; loperamide and codeine, 298; nifedipine, 399; prednisolone, 399, 496; ranitidine, 914; sulfasalazine, 298, 1007; tamoxifen, 914; tiotidine, 399; trimipramine, 399; vitamin C, 496
Geiger, Gail S. (author) elevations in serum transaminases and alkaline phosphatase secondary to papaverine hydrochloride, 127
Gelman, Cynthia J.R. (coeditor) Current Therapeutic Findings, 219
General Medicine (CTF), acetazolamide, 399; 1-alpha-acetylmethadol, 496; antacids, 914; aspirin, 298; chlorpheniramine maleate, 496; danazol, 58; dipyrone, 143; drug withdrawal, 399; interferon, 220; ipratropium, 704; mannitol, 611; medroxyprogesterone acetate, 611; phosphorus, 914; phyostigmine, 611; pneumococcal vaccine, 220, 399; potassium iodide, 496; prazosin, 59; propranolol, 611; scopolamine, 496; silver nitrate, 220; sodium bicarbonate, 143; toxic shock syndrome, 220; vitamin D, 704; zomepirac, 220, 298
General, Joyce A. (author) hypertensive crisis resulting from avocados and a MAO inhibitor, 904
Gentamicin, comparative evaluation, 847; in infectious disease (CTF) 298; in pediatrics (CTF) 145; nephrotoxicity, 248; nephrotoxicity, in adverse drug reactions (CTF) 146; pharmacokinetics in adjusting dose, 651
Gearty, Anne Fondriest (coauthor) see Lee, Mary, 782
Gerbino, Philip P. (coauthor) see Tannenbaum, Renee P., 766
Geriatrics (CTF), amitriptyline, 611; chloral hydrate, 298; digitoxin, 704; diuretics, 704; drug therapy, 220; imipramine, 704; vaccines, 220; zinc sulfate, 1007
Geriatrics, counseling the hearing-impaired older adult, 377; epidemiology of serum potassium levels, 467; issues and priorities for research, 111; pharmacy's contribution to geriatric care, 569; rational use of psychoactive drugs, 940; White House Conference on Aging (ed), 383
Geriatrics and Gerontology, 111, 377, 467, 569, 777, 887
Gess, Kathy, (coauthor) see Wallace, Sylvia M., 651
Gilbert, Ray (coauthor) see Rosenblum, David, 286
Glaucoma, association with drugs and chemicals, 434
Glucagon, in gastroenterology (CTF) 399
Glycerol, in nutrition (CTF) 915
Goel, K.M., (coauthor) see Baile, G.R., 388
Gold Sodium Thiomalate, in obstetrics/gynecology (CTF) 400
Gonadotropins, in obstetrics/gynecology (CTF) 400
Gonzales, James (author) intraarticular amphotericin B, 884
Gorecki, Dennis K.J., (coauthor) see Wallace, Sylvia M., 651
Gorochategui, Martin (coauthor) see Holt, Robert J., 288
Gotz, Vincent P. (author) bullae associated with allopurinol, 490
Gourley, Dick R. (author) Locus of Control Dimensions Among Senior Pharmacy Students Electing Post-Pharm.D. Residencies, 43
Goyan, Jere E., pharmacists and the FDA, 318
Groleau, M. (coauthor) see Henri, L., 696
Grossman, Joshua B. (author) Wolff-Parkinson-White syndrome, 910
Guandel, R. in cardiovascular disease (CTF) 704

H

Halkenscheid, J.C.M. (coauthor) see Vree, T.B., 194
Halcionide, in pediatrics (CTF) 400
Hale, William E. (coauthor) see Stewart, Ronald B., 467
Hall, David H. (coauthor) see Salem, Ronald B., 992
Haloperidol, acute dystonic reaction, in adverse drug reactions (CTF) 60; in pediatrics (CTF) 820; in psychiatry (CTF) 401, 706; psychotic exacerbation, 209; teratogenicity, 556
Halothane, renal failure, in adverse drug reactions (CTF) 613, 706
Hansen, Ebba Holme (coauthor) see Hemminki, Elina, 27
Hardin, Thomas C. (author) vagueness of term: *patient-oriented*, 909
Harralson, Arthur F. (coauthor) see Ambrose, Peter J., 389, 810
Harris, Patricia Roberts (author) The Health and Well-Being of Mothers and Children—Remarks, 567
Hart, Linda L. (coauthor) see Haupt, Bridget, 885; (editor) DIAS Rounds, 287, 884
Hartman, Charles R. (coauthor) see Generali, Joyce A., 904
Hatunou, Nabil S. (coauthor) see Davis, W. Marvin, 290
Haupt, Bridget (author) phenacetin and cancer of urinary tract, 885
Hays, Dennis P. (author) Teratogenesis: A Review of the Basic Principles with a Discussion of Selected Agents: Part I, 444; Part II, 542; Part III, 639; (coauthor) see DeNicola, Lucian K., 601
Health and Human Services, Department of, block grants proposed, 621; GAO releases report, 414; new administration, 414; new biological response modifier program announced, 713; Schweiker on cost-control, 414; workshop on maternal and infant health, 621
Health Care, evaluating clinical programs, 684
Health Resources Administration, capitation grants, 317
Hearing, counseling the hearing-impaired older adult, 377
Heister, Chiel (author) book review, 295; (coauthor) see Friesen, W.T., 325; (coauthor) see Vree, T.B., 194
Helling, Dennis K. (author) Effects of Capitation Payment for Pharmacy Services on Pharmacist-Dispensing and Physician-Prescribing Behavior: I. Prescription Quantity and Dose Analysis, 581; (author) Family Practice Pharmacy Service, 971; (coauthor) see Norwood, G.

Joseph, 656, (coauthor) see Prince, Randall A., 863
Hematology (CTF), anti-inhibitor coagulant complex, 399; choline magnesium trisilicate, 704; ibuprofen, 298; plasmapheresis, 611; platelet dysfunction, 611; salsalate, 220; thrombotic thrombocytopenic purpura, 496; triglycidyl vasopressin, 298; uric acid mustard, 59
Hemminki, Elina (author) Number and Type of Psychotropic Drugs on the Scandinavian Market in 1950-1977, 27
Hemodialysis, in psychiatry (CTF) 820
Hemoglobin, glycosylated, diabetic control assessment, 175
Hemolytic Anemia, induced by methyldopa, 488
Hendles, Leslie (author) Influence of Gender on Theophylline Dosage Requirements in Children with Chronic Asthma, 338; (author) letter, the interaction of cimetidine and theophylline, 808
Henri, L. (author) retroperitoneal fibrosis after treatment with propranolol, 396
Heparin, in cardiovascular disease (CTF) 610; in renal disease (CTF) 145; thrombocytopenia, in adverse drug reactions (CTF) 613
Hepatitis B Vaccine, in infectious disease (CTF) 59
Hepatotoxicity, elevations in serum transaminases and alkaline phosphatase secondary to papaverine hydrochloride, 127
Heyler, Charles D. (coauthor) see Prince, Randall A., 372, 863
Heroin, in oncology (CTF) 820
Hill, John W. (coauthor) see Gourley, Dick R., 43
Histamine, receptor antagonist, use of cimetidine for mastocytosis, 180
Hodgson, Teresa G. (author) letter, bad taste from cefamandole, 136
Hogan, Linda C. (coauthor) see Generali, Joyce A., 904
Holmes, C.J. (coauthor) see Ausman, R.K., 440
Holt, Robert J. (author) hyperglycemia associated with propranolol and chlorpromazine coadministration, 599; (coauthor) hypothyroidism associated with moxalactam treatment of septic sternoclavicular arthritis due to *Citrobacter diversus*, 288
Honda, Dennis H. (author) amikacin penetration into synovial fluid during treatment of septic arthritis, 284
Hooper, Alan W. (author) letter, comment on cephalosporin-aminoglycoside toxicity, 697
Horn, John R. (author) book review, 396, 701
Huber, Stephen L. (author) Internal Standards: Rationale for Use in Drug Utilization Review Program, 789
Hutchinson, Richard A. (coauthor) see Kaczmarek, Elizabeth R., 117
Hydralazine, in anesthesiology (CTF), 818; in obstetrics/gynecology (CTF) 221; in pregnancy, 24; hepatotoxicity, in adverse drug reactions (CTF), 300; pancytopenia, fever, jaundice, in adverse drug reactions (CTF) 821
Hydrochlorothiazide, acute interstitial nephritis, in adverse drug reactions (CTF) 300
Hydrocortisone, topical complications, in adverse drug reactions (CTF) 706
Hydrogen Peroxide, ulcerative colitis, in adverse drug reactions (CTF) 821
L-5-Hydroxytryptophan, scleroderma-like illness, in adverse drug reactions (CTF) 60
Hydroxyzine, in anesthesiology (CTF) 58; in toxicology (CTF) 498
Hyoscine Butylbromide, in gastroenterology (CTF) 704
Hyperglycemia, with propranolol and chlorpromazine, 599
Hypertension, methods of modifying compliance behavior, 8; primary pulmonary, in pulmonary disease (CTF) 221; treatment in pregnancy, 21
Hypertensive Crisis, with avocados and a MAO inhibitor, 904
Hyperthermia, Malignant, in anesthesiology (CTF) 219
Hypnotics, effect of capsule color, 492
Hyperosmolar, fentanyl overdose, 129
Haukio-Tilskä, Lisa (coauthor) see Erick, Jeffrey Keith, 133

I

Iatrogenic Disease, in adverse drug reactions (CTF), 500
Ibuprofen, hyponatremia, in adverse drug reactions (CTF) 300; in hematology (CTF) 298; inflammation studies, 5; in obstetrics/gynecology (CTF) 59; in rheumatology (CTF) 299; in toxicology (CTF) 300
Idoxuridine, teratogenicity, 550
Ignoffo, Robert J. (author) book review, 141
Isoniazid, product still available, 828
Imipramine, in geriatrics (CTF) 704; plasma concentration monitoring of hydroxylated metabolites, 263; treatment of cataplexy, 260; withdrawal symptoms, in adverse drug reactions (CTF) 1009
Immunotherapy, local nasal, in pulmonary disease (CTF) 1008
Indomethacin, decreased renal function, in adverse drug reactions (CTF) 916; hyperkalemia, in adverse drug reactions (CTF) 62, 821; in rheumatology (CTF) 60
Industry, Pharmaceutical, Kellogg fellowships, 927; orphan drug problem, 714; response to the drug regulation system, 799; SmithKline and French, grants to colleges of pharmacy, 926; Upjohn, capital and research spending, 927
Infant Formula, Act of 1980, 76
Infectious Disease (CTF), acyclovir, 914; antibiotics, 496; bacampicillin, 611, 705; bacitracin, 143; cefadroxil, 59, 144, 705; cefadroxil, 220; cefamandole, 496; cefazolin, 705; cefotaxime, 914; cefoxitin, 298; cefuroxime, 399; cephalaxin, 611; cinoxacin, 59, 1007; clotrimazole, 221; disseminated gonococcal infection, 612; doxycycline, 1007; endocarditis, 221; flucytosine, 59; gentamicin, 298; hepatitis B vaccine, 59; ketoconazole, 144; levamisole, 298; metronidazole, 59, 143, 399, 1007; moxalactam, 914; netilmicin, 399, 496, 612; pelvic inflammatory disease, 909; procaine penicillin G, 400; rifampin, 496;

rosaramicin, 612; tetanus immune globulin, 59; ticarcillin, 221, 914
Inflammation, studies with nonsteroidal antiinflammatory agents, 4
Influenza Vaccine, literature analysis, 913
Inoue, Fumio (author) letter, psychotropic drug history chart, 134
Insulin, in endocrinology (CTF) 819; in gastroenterology (CTF) 914; in intravenous therapy (CTF) 144; in ophthalmology (CTF) 915
Intercept®, cut finger syndrome, 292
Interferon, HHS awards contract for production, 76; in general medicine (CTF) 220; in oncology (CTF) 820; research organization, 156
International Conference of Drug Registration Authorities, excerpts from keynote address, 236
Interstitial Nephritis, in adverse drug reactions (CTF) 222
Intralipid®, effects of dextrose, amino acids, and selected electrolytes, 184
Intravenous Therapy (CTF), amino acids, 705; amphotericin B, 612; brylindol tosylate, 400; cimetidine, 820; diazepam, 59, 400; emulsion compatibility, 184; insulin, 144; intravenous fat emulsions, 497; phenytoin, 612; tobramycin, 298
Intravenous Fat Emulsion, in adverse drug reactions (CTF) 402, 497
Investigational Drug Information, 578
Iodine, hyperthyroidism, in adverse drug reactions (CTF) 1009
Ipratropium, in general medicine (CTF) 704
Ipecac Syrup, in toxicology (CTF) 401
Iron, in toxicology (CTF) 60
Isobutyl Nitrite, severe tracheobronchitis with inhalation, 51
Isoipinosine, FDA denies approval, 1020

J

Jackson, Eric A. (editor) *New Drug Evaluations*, 94, 325, 422, 623, 838, 932
Jackson, J. Edward (author) letter, more on cimetidine—*theophylline* interaction, 89
Jacobs, Richard (author) see **LeFrock, Jack L.**, 951
Jeffery, William H. (author) letter, more on nadolol, 603
Jeffrey, Louis P. (author) see **Rich, Darryl S.**, 214
Jinks, Martin J. (author) see **Chernak, Gail**, 377
Johnson, Jeanne A. (author) see **Richards, Mark L.**, 341
Johnson, June Felice (author) *Pneumocystis Carinii* Pneumonia: Review with a Case Study, 732
Johnston, Timothy S. (author) *Diagnosis and Treatment of Five Parasites*, 103
Jones, Mark E. (author) see **Helling, Dennis K.**, 581; (author) see **Norwood, G. Joseph**, 656; (author) see **Prince, Randall A.**, 863
Judson, Franklin N. (author) letter, compliance behavior and adverse reactions in women given a single 2-gram dose of metronidazole, 606
Jusko, William J. (author) see **DeVane, C. Lindsay**, 263

K

Kaczmarek, Elizabeth R. (author) *PPIs: Community Pharmacists' Compliance*, 117
Kanamycin, comparative evaluation, 855
Kapel, David E. (author) see **Gourley, Dick R.**, 43
Kaul, Alan F. (author) *Postgraduate Pharmacy Fellowships*, 981
Kelly, Kim L., *ACCP News*, 83, 247, 521; (author) letter of reply, 136
Kenaley, Karen A. (author) see **Richards, Mark L.**, 341
Kennedy, Robert M. (author) see **Salinas, Ernest**, 384
Kerkhof, K. (author) see **Ausman, R.K.**, 440
Kesson, Colin M. (author) see **Baile, G.B.**, 492; (author) see **Marshall, Sally M.**, 598
Ketamine, in anesthesiology (CTF) 219, 610
Ketocaine, in obstetrics/gynecology (CTF) 144
Ketoconazole, in dermatology (CTF) 496; in infectious disease (CTF) 144; new antifungal agent, 828
Ketotifen, in pulmonary disease (CTF) 60
Kidney Function, influence of urine flow on renal clearance of creatinine, 194
Kimelblatt, Bruce J. (author) see **Bauman, Jay H.**, 808
Kinsella, J.M. (author) comment on parasitic diseases, 603
Kizka, Edwin P. (author) see **Feldman, Marvin J.**, 54
Kleinberg, Michael L. (author) comment on antibiotic stability, 291
Knouse, Brent F. (author) comment on phenytoin dosage, author's reply, 215
Koda, R.T. (author) see **Lien, E.J.**, 434
Koseoff, Jacqueline (author) *Needs Assessment: Selecting Goals for a Clinical Program*, 986; (author) see **Fink, Arlene**, 536
Koshiro, Akira (author) *Prediction of the Stability of Metoclopramide Injection in Parenteral Admixtures*, 331
Kowalski, Steven F. (author) see **LeFrock, Jack L.**, 951
Kramer, Paul A. (ed) *Clinical Pharmacokinetics versus Therapeutic Drug Monitoring—A Perspective for Pharmacists*, 474
Kumar, Ashir (author) *Moxalactam in treatment of recurrent Escherichia coli meningitis and ventriculitis in an infant with agammaglobulinemia*, 50; (author) see **Kumar, Kusum**, 802
Kumar, Kusum (author) reversible neutropenia associated with ampicillin therapy in pediatric patients, 802
Kundsin, R.B. (author) see **Ausman, R.K.**, 440

L

Lactose, in gastroenterology (CTF) 1007
Laetrile, National Cancer Institute report, 621

Lamy, Peter P. (editor) *Geriatrics and Gerontology*, 111, 377, 467, 569, 777, 887; (ed) 1981—*The Year of the White House Conference on Aging*, 383; (author) *Nutrition and the Elderly*, 887
Lawless, Leo M. (author) comment on theophylline overdose, 215
Lead Acetate, hair dye warning, 158
Lech, John G. (author) see **Covalla, John R.**, 51
Lee, Dong (author) see **Tornatore, Frank L.**, 209
Lee, Mary (author) *Tartrazine-Containing Drugs*, 782
Lee, Winston (author) see **James, Sara**, 84
LeFrock, Jack L. (author) *Use of Cefamandole in the Treatment of Soft Tissue and Skeletal Infections*, 951; (author) see **Richards, Mark L.**, 341
Leibowitz, Philip E. (author) letter, pharmacy ethics—is it time for a "Bill of Rights" for pharmacists?, 390
Letters to the Editor, bad taste from cefamandole, 136; British National Formulary and child-resistant containers, 604; cimetidine and sinus bradycardia, 492; comment on an independent national organization for pharmacy technicians, 699; author's comments 700; comment on antibiotic stability, author's reply, 291; comment on antiepileptic pharmacokinetics, 214; comment on aspirin bioavailability article, 53; comment on aspirin bioavailability monitoring, author's reply, 291; comment on cephalosporin-aminoglycoside toxicity, authors' reply, 697; comment on effect of cimetidine on theophylline clearance, 808; comment on intravenous emulsion compatibility, authors' reply, 808; comment on lorazepam withdrawal, 133; comment on medication administration article, 136; comment on nadolol article, 215; comment on one designation for pharmacists, 493; comment on parasitic diseases, author's reply, 390; comment on parasitic diseases, 603; comment on PD designation, 810; comment on phenytoin dosage, 215; comment on the comment on nadolol article, 603; comment on the tenuring, 909; comment on theophylline overdose, 215; comments on acalculosis, 132; compliance behavior and adverse reactions in women given a single 2-gram dose of metronidazole, 606; controlling nausea and vomiting in pregnancy, 1002; correction to erythromycin ototoxicity, 133; correction to zomepirac article, 1002; the cut finger syndrome—Intercept® vaginal suppositories, 292; diabetic urine testing in South Carolina, 792; effect of capsule color on hypnotic efficacy, 492; European Economic Community and pharmacy practice, comment, 810; interaction of cimetidine and theophylline, 808; intravenous admixture survey, 999; lack of effect of cimetidine on theophylline clearance, 389; Michaelis-Menten across the floating bridge, 132; more on lorazepam withdrawal, 134; more on nadolol, 603; non-estrogen treatment for menopausal symptoms, 132; ol' Doc Adams vs. 'dig' levels, 391; pharmacokinetics of the 1.73-m² person, 214; pharmacy ethics—is it time for a "Bill of Rights" for pharmacists?, 390; pharmacy-nursing Kardex® rounds, a communication technique, 216; PRN rounds, 1001; propranolol and thyroxine metabolism, 131; psychotropic drug history chart, 134; the rise and fall of notional pricing, 391; the tenuring, 494; thrombocytopenia associated with metoclopramide, 999; toxic interaction of propranolol and narcotic analgesics, 290; an unrecognized cause of warfarin resistance, 131; use of a hand-held programmable calculator in performing neonatal parenteral nutrition solution calculations, 54; vagueness of term, *patient-oriented*, 909; Wolff-Parkinson-White syndrome, 910
Levamisole, in infectious disease (CTF) 298; in oncology (CTF) 144; in rheumatology (CTF) 401
Levodopa, in neurology (CTF) 298, 497, 612, 914
Levothyroxine, cardiac arrest, in adverse drug reactions (CTF) 500
Levy, Gerhard (author) *Accreditation Standards for Doctor of Pharmacy Programs*, 470; (author) *Impressions of a Pharmaceutical Scientist on a Visit to the People's Republic of China*, 674; (author) *Pharmaceutical Education in the Future*, 590
Licorice, hypokalemia, in adverse drug reactions (CTF) 146
Lidocaine, fatal heart rate decelerations, in adverse drug reactions (CTF) 500; in toxicology (CTF) 222
Lien, E.J. (author) *Structure-Effect Sorting of Drugs: V. Glaucoma and Cataracts Associated with Drugs and Chemicals*, 434
Lincomycin, teratogenicity, 550; treatment of actinomycosis, 101
Lipson, David P. (author) see **Helling, Dennis K.**, 581; (author) see **Norwood, G. Joseph**, 656
Lisuride, in neurology (CTF) 705
Lithium, in psychiatry (CTF) 60, 612; nephrotic syndrome, in adverse drug reactions (CTF) 613; neurological side effects, in adverse drug reactions (CTF) 146; severe poisoning, 598; teratogenicity, 555
Literature, 137, 217, 295, 393, 701, 815, 911
Lockridge, Robert (author) see **Polk, Ron E.**, 15
Long-Term Care Centers, money provided, 235
Longe, R. Leoro (author) *The Thorax and the Lungs*, 166
Loperamide, in gastroenterology (CTF) 298
Lorazepam, comment on withdrawal, 133; in psychiatry (CTF) 612
Lorazepam, in cardiovascular disease (CTF) 143
Lohr, Kathleen N. (author) *Quality Assurance and Clinical Pharmacy: Lessons from Medicine*, 758
Lowenthal, David T. (author) see **Affrime, Melton B.**, 964
Lungs, physical assessment, 166
Lupus Erythematosus, in dermatology (CTF) 611; *Lupus Nephritis*, in renal disease (CTF) 401
Lymecycline, in obstetrics/gynecology (CTF) 915

M

Macfie, Helen L. (author) *Amiloride*, 94
MacKinnon, Jan J. (author) book review, 139

MacKinnon, Glenda L. (author) see **Parker, William A.**, 806
Magnesium Sulfate, in obstetrics/gynecology (CTF) 612, 1008
Mangione, Robert A. (author) see **Torre, Michael S.**, 175
Mann, James L. (author) see **Broostad, Andrea**, 216
Mannion, James C. (author) *Cephalosporin-Aminoglycoside Synergistic Nephrotoxicity: Fact or Fiction?*, 248; (author) letter, authors' reply, 697
Mannitol, in general medicine (CTF) 611; in rheumatology (CTF) 1008
Maprotiline, in psychiatry (CTF) 706
Markowitz, Sheldon M. (author) see **Polk, Ron E.**, 751
Marks, Ronald G. (author) see **Stewart, Ronald B.**, 467
Marshall, Sally M. (author) severe lithium poisoning, 598
Masamori, Debra (author) cimetidine and allograft rejection, 278
Masiakowski, Carla J. (author) letter, intravenous admixture survey, 999
Massoud, Neil (author) *Update on the Treatment of Bacteriuria*, 738
Matosystosis, treatment with cimetidine, 180
Matzka, Gary R. (author) elevated serum phenytoin concentrations in a uremic patient when measured by enzyme-multiplexed immunoassay, 386; (author) see **Wilson, A.L.**, 21
Mayhall, C. Glen (author) see **Polk, Ron E.**, 751
McClard, Thomas P. (author) letter, comment on one designation for pharmacists, 493
McFarlane, Michael (author) see **Generali, Joyce A.**, 904
McGhan, William F. (author) *Dilemmas in Evaluating Health Care and Clinical Programs*, 684; (author) see **Stimmel, Glen L.**, 665
McGraw, Benjamin F. (author) *Sucralfate*, 578
McKenney, James M. (author) *Methods of Modifying Compliance Behavior in Hypertensive Patients*, 8
McLean, William N. (ed) *An Omen for Future Clinical and Administrative Managers*, 900
McLeod, Don C. (author) letter, correction to zomepirac article, 1002; (author) *Zomepirac*, 522; (ed) *Accreditation Standards*, 472; (ed) *The Legacy of Donald E. Francke: DICP—A Fifteen-Year Commitment to Clinical Pharmacy*, 99
Measles Vaccine, thrombocytopenia, in adverse drug reactions (CTF) 1009
Mebendazole, treatment of *Ascaris lumbricoides*, 108; treatment of *Enterobius vermicularis*, 106; treatment of *Trichuris trichiura*, 107
Meclofenamate Sodium, absorption with aspirin, 4
Meclofenamate, thrombocytopenia, 999
Meclofenamate, stability in parenteral admixtures, 331
Medicaid, effect of pharmacist intervention, 582
Medical Device Firms, must alert FDA of safety problems, 527
Medicare, hospital deductible increased, 157
Medroxyprogesterone Acetate, in general medicine (CTF) 611; in obstetrics/gynecology (CTF) 59
Mefenorexol, treatment of parasites, 104
Meningitis, E. coli, treatment with moxalactam, 50; in pediatrics (CTF) 706
Menopause, non-estrogen treatment, 132
Mephobarbital, hepatic necrosis, in adverse drug reactions (CTF) 402
Meprobamate, in toxicology (CTF) 60
Mercury, in toxicology (CTF) 401
Mesadone, choreic movements, in adverse drug reactions (CTF) 146
Meizhaqualone, in toxicology (CTF) 613
Methohexital, in anesthesiology (CTF) 297
Methotrexate, in oncology (CTF) 221, 612, 915
Methsuximide, in neurology (CTF) 914
Methyldopa, colitis, in adverse drug reactions (CTF) 710; hemolytic anemia and parkinsonism, 488; systemic lupus-like syndrome, in adverse drug reactions (CTF) 916; in pregnancy, 22
Methylphenidate, for narcolepsy, 259; in psychiatry (CTF) 612
Methylprednisolone, cardiac arrest, in adverse drug reactions (CTF) 1009; in oncology (CTF) 497; in renal disease (CTF) 821; in rheumatology (CTF) 221, 401
Metoclopramide, in cardiovascular disease (CTF) 219; in obstetrics/gynecology (CTF) 820
Metronidazole, treatment of parasites, 104
Metronidazole, compliance behavior and adverse reactions with a single 2-gram dose, 606; in infectious disease (CTF) 59, 144, 399; in pediatrics (CTF) 299; in renal disease (CTF) 60; new drug evaluation, 838; pseudomembranous colitis, in adverse drug reactions (CTF) 613; teratogenicity, 550; treatment of *Entamoeba histolytica*, 109; treatment of *Giardia lamblia*, 107
Mexiletine, in cardiovascular disease (CTF) 704, 819
Miconazole, in dermatology (CTF) 819
Microvase, thawing of frozen parenteral nutrition solutions, 440
Milavetz, Gary (author) see **Hendles, Leslie**, 808
Miller, Donald R. (author) *Combination Use of Nonsteroidal Antiinflammatory Drugs*, 3
Mills, D.G. (author) see **Bayliff, C.D.**, 801
Minocycline, pigmentation, in adverse drug reactions (CTF) 22; treatment of actinomycosis, 101
Minoxidil, in cardiovascular disease (CTF) 143, 219; in pregnancy, 24; in toxicology (CTF) 401
Mitridine, idiopathic orthostatic hypotension, 1006
Moore, Charles R. (author) see **Beck, Diane E.**, 693
Moore, Gerald F. (author) see **Johnson, June Felice**, 732
Morphine, catatonia, in adverse drug reactions (CTF) 222; in anesthesiology (CTF) 58, 610, 818; in obstetrics/gynecology (CTF) 400, 497, 820
Morris, Herbert (author) see **Salinas, Ernest**, 384
Moxalactam, hypoprothrombinemia, 288; in infectious disease (CTF) 914; treatment of recurrent meningitis, 50
Myers, M.L. (author) see **Bayliff, C.D.**, 801

N

- Nabilone**, in psychiatry (CTF) 915
- Nadolol**, in pregnancy, 54
- Nalidixic Acid**, in infectious disease (CTF) 819; in obstetrics/gynecology (CTF) 497; photodermatitis after minimal sun exposure, 126
- Naloxone**, cardiac arrest, in adverse drug reactions (CTF) 146; continuous infusion for narcotic overdose, 945; in anesthesiology (CTF) 143; in endocrinology (CTF) 704; in neurology (CTF) 1007; in psychiatry (CTF) 401; in psychiatry (CTF) 1008; in toxicology (CTF) 498
- Naproxen**, bronchospasm, in adverse drug reactions (CTF) 300; in obstetrics/gynecology (CTF) 400, 915; in renal disease (CTF) 299; in rheumatology (CTF) 613
- Narcology**, drug treatment, 257
- National Clearinghouse for Poison Control Centers**, new directory available, 77
- Neomycin**, neuromuscular blockade, in adverse drug reactions (CTF) 613
- Nester, Thomas J.** (author) letter, propranolol and thyroxine metabolism, 131
- Netilmicin**, in infectious disease (CTF) 399, 496, 612
- Neurology (CTF)**, allopurinol, 497, 705; 4-aminopyridine, 400; amitriptyline, 705; amitriptyline/perphenazine, 820; anticonvulsants, 59; carbamazepine, 144; choline, 298, 820; collagenase, 497; corticosteroids, 497; deprenyl, 497; levodopa, 298, 497; levodopa/benserazide, 914; levodopa/carbidopa, 612; lisuride, 705; methsuximide, 914; naloxone, 1007; pergolide mesylate, 914; phenytoin, 497; pramipexole, 497; propranolol, 400, 705; ranitidine, 1007; sodium valproate, 497; thiopental-pentobarbital, 400; triethylcyclohexanecarboxylate, 298; valproate sodium, 221; zomepirax, 612, 1007
- New Drug Applications**, reflections and predictions, 793
- Niclosamide**, treatment of parasites, 104
- Nifedipine**, in cardiovascular disease (CTF) 704, 819, 914; in gastroenterology (CTF) 399; in psychiatry (CTF) 613
- Nifurtimox**, treatment of parasites, 104
- Nitrazole**, treatment of parasites, 104
- Nitrites**, treatment of diffuse esophageal spasm, 806
- Nitroglycerin**, in cardiovascular disease (CTF) 297, 398, 610; in renal disease (CTF) 145
- Nitroprusside**, in cardiovascular disease (CTF) 704
- Nitrous Oxide**, in general medicine (CTF) 819
- Noback, Richardson K.** (coauthor) see **Payne, Vaughn W.**, 902
- Norwood, G. Joseph** (author) Effects of Capitation Payment for Pharmacy Services on Pharmacist-Dispensing and Physician-Prescribing Behavior: II. Therapeutic Category Analysis, Over-the-Counter Drug Usage, and Drug Interactions, 656; (coauthor) see **Helling, Dennis K.**, 581
- Nutrition**, in the elderly, 887
- Nutrition (CTF)**, ascorbic acid, 1007; glycerol, 915; nutrients, 298; oral contraceptives, 221; pangamic acid, 298; vitamin A, 144; vitamin C, 400

O

- O'Broovich, Milton** (author) book review, 141
- Obstetrics**, rhotidine for premature labor, 425
- Obstetrics/Gynecology (CTF)**, antibiotics, 612; anticonvulsants, 59, 299, 1007; aspirin, 1008; asthma, 299; Bendectin®, 915; bromocriptine, 705, 612; captopril, 705; cefamandole, 299; chlorpheniramine, 705; corticosteroids/sulfasalazine, 299; cortisol/17 α -hydroxyprogesterone caproate, 221; Debondex®, 1008; diethylstilbestrol, 497; digoxin, 820; dinitrochlorobenzene, 1008; dipyrindole/aspirin, 144; estrogens, 144; ethinyl estradiol, 59; gold sodium thiomalate, 400; gonadotropins, 400; hydralazine, 221; ibuprofen, 59; ketocaine, 144; lymecycline, 915; magnesium sulfate, 612, 1008; medroxyprogesterone acetate, 59; metoprolol, 820; morphine, 400, 497, 820; nalidixic acid, 497; nifedipine, 400, 915; oral contraceptives, 400; povidone-iodine, 221, 497; primidone, 1008; propranolol, 705, 1008; scopalamine, 59; sulfasalazine/corticosteroids, 299; theophylline, 59
- Ogawa, O. A.** (author) methyldopa-induced hemolytic anemia and parkinsonism, 488
- Oncology (CTF)**, aminoglutethimide, 299; antineoplastics, 59; BCNU, 612; bleomycin, 299; CCNU, 497; cisplatin, 612, 820, 1008; cyclophosphamide, 705; cytarabine/thioguanine, 144; delta-9-tetrahydrocannabinol, 705, 820; doxorubicin, 400, 497; estramustine, 915; estrogens, 144; etoposide, 144; 5-fluorouracil, 144, 400; gastrointestinal malignancy, 144; heroin, 820; human leukocyte interferon, 820; levamisole, 144; methotrexate, 220, 612, 915; methylprednisolone, 497; streptozotocin, 400; tamoxifen, 299, 915; teposide, 144; tetrahydrocannabinol, 59; total parenteral nutrition, 1008; vincristine, 400; vitamin E, 299; warfarin, 497
- Ophthalmology (CTF)**, acyclovir, 221; amikacin, 221; cimetidine, 497; clonidine, 1008; epinephrine compounds, 400; insulin, 915; phenylephrine, 144
- Oral Contraceptives**, endometrial cancer, in adverse drug reactions (CTF) 146; in nutrition (CTF) 221; in obstetrics/gynecology (CTF) 400; interaction with antibiotics, 280; risk of myocardial infarction, in adverse drug reactions (CTF) 1009; systemic lupus erythematosus, in adverse drug reactions (CTF) 300
- Orr, Leo E.** (author) Potential of Myelosuppression from Cancer Chemotherapy and Thiazide Diuretics, 967
- Orthostatic Hypotension**, in cardiovascular disease (CTF) 143
- Over-the-Counter Drugs**, effects of capitation payment, 659
- Owen, John W.** (coauthor) see **Zelnio, Robert N.**, 309
- Oxazepam**, withdrawal convulsions, 487
- Oxygen**, warning for emergency kits, 318

P

- Pancreatic Enzymes**, in gastroenterology (CTF) 819
- Pangamic Acid**, in nutrition (CTF) 298
- Papapoulos, Philip** (coauthor) see **LeRock, Jack L.**, 951
- Papaverine**, abnormal liver function tests, in adverse drug reactions (CTF) 146; elevations in serum transaminases and alkaline phosphatase, 127
- Parasites**, diagnosis and treatment of *Enterobius vermicularis*, *Giardia lamblia*, *Trichuris trichiura*, *Ascaris lumbricoides*, *Entamoeba histolytica*, 103
- Parathion**, in toxicology (CTF) 821
- Parenteral Solutions**, frozen storage and microwave thawing, 440; stability of meflofenoxate, 331
- Parker, William A.** (author) nitrates in the treatment of diffuse esophageal spasm, 806
- Parkinsonism**, induced by methyldopa, 488
- Pathak, Dev S.** (author) Evaluation of Clinical Programs: An Operational Framework, 459; (ed) Research Methodology, 459, 536, 584, 758, 892, 986
- Patient Counseling**, hearing-impaired older adult, 377
- Patient Education**, methods of modifying compliance behavior, 8
- Patient Package Inserts**, national distribution center, Ja-cit 1; community pharmacists' compliance, 117; postponed pending review, 621
- Patient Survey**, of satisfaction, 892
- Patry, Roland A.** (coauthor) see **Huber, Stephen L.**, 789
- Payne, Vaughn W.** (author) use of colistepal in a patient with digoxin toxicity, 902
- Pearson, Robert E.** (author) Drug Information Services Activity, 1961-1979: A Citation Analysis, 272
- Pediatrics**, child health deficiencies tied to income and race, 829; dosage requirements in chronic asthma, 338; health and well-being of mothers and children, 567; reversible neutropenia associated with ampicillin, 802
- Pediatrics (CTF)**, albumin, 144; amikacin, 705; aminophylline, 299; ampicillin/chloramphenicol, 59; ampicillin/nafcillin, 820; anticonvulsants, 705; aspirin, 400; baclofen, 915; betamethasone, 59; cefaclor, 1008; cefadroxil, 915; chloramphenicol, 59, 145, 497, 820; contraception and breast-feeding, 1008; cromolyn sodium, 145; danazol, 820; febrile seizures, 221; furazolidone, 497; gentamicin, 145; halcinonide, 400; haloperidol, 820; metronidazole, 299; nafcillin/ampicillin, 820; neonatal apnea, 820; neonatal meningitis, 706; phenobarbital, 1008; phenytoin, 612; prostaglandin E, 497; pyridoxine, 706; Ray's syndrome, 612; sulfisoxazole, 221; theophylline, 221, 498; thiamine, 401; tyrosine, 1008; verapamil, 498; vidarabine, 145
- Pelvic Inflammatory Disease**, in infectious disease (CTF) 298
- Penicillamine**, cholestatic jaundice, in adverse drug reactions (CTF) 718
- Penicillin**, granulocytopenia, 289; in infectious disease (CTF) 400; teratogenicity, 55; treatment of actinomycosis, 101
- Pentamidine Isethionate**, acute pancreatitis, in adverse drug reactions (CTF) 402; treatment of parasites, 104; treatment of *Pneumocystis carinii* pneumonia, 733
- Pepper, Gnette A.** (author) book review, 295
- Perez, Casilda**, (coauthor) see **Holt, Robert J.**, 288
- Pergolide Mesylate**, in neurology (CTF) 914
- Peritoneal Dialysis**, in dermatology (CTF) 496
- Pesonen, Teriti** (coauthor) see **Hemminki, Elina**, 297
- Personnel Placement**, 71, 152, 228, 229, 306, 307, 308, 309, 397, 405, 406, 410, 506, 507, 617, 707, 708, 720, 827, 832, 919, 1016
- Petersen, Eric D.** (coauthor) see **Baumgartner, Thomas G.**, 908
- Petroleum Distillate**, toxicities with intravenous and subcutaneous administration, 693
- Pezatti, John T.** (author) letter, cimetidine and sinus bradycardia, 492
- PharmACE 81 Test Questions**, 73, 155, 233, 315, 411, 505, 618, 711, 823, 921, 1017
- Pharmaceutical Manufacturers Association**, commission on drugs, 925
- Pharmacist Prescribing**, U.S. pilot project, 665
- Pharmacokinetics**, adjusting gentamicin dosage, 651; amiloride, 95; aminoglycosides, 853; antimicrobial penetration into cerebrospinal fluid, 341; body surface area, 214; captopril, 933; dosage requirements of theophylline in children with chronic asthma, 339; indomethacin, 3; metabolites of imipramine and desipramine, 265; metronidazole, 839; naloxone, 946; nonsteroidal antiinflammatory agents, 3; therapeutic drug monitoring, 474; trimethoprim, 325; vancomycin in dialysis patients, 15; zomepirax, 523
- Pharmacy, Community**, compliance with patient package inserts, 117; preceptors' views of clerkships, 766
- Pharmacy Education**, accreditation standards for doctor of pharmacy programs, 470, 472; community pharmacy clerkships, national survey, 767; in the future, an opinion, 590; postgraduate fellowships, 981; senior pharmacy students electing post-Pharm.D. residencies, 43
- Pharmacy Practice**, capitation payment for pharmacy services, effect on pharmacist and physician, 581; continuing education, views on controversy (ed) 928; evaluating clinical programs, methodological guidelines, 536; family practice service, 971; geriatric pharmaceutical care, 112; goals for a clinical program, 986; pharmacy-nursing Kardec® rounds, 216; recognition of clinical pharmacy, 267
- Phenacetin**, cancer of the urinary tract, 885
- Phencyclidine**, in toxicology (CTF) 145, 498; overview of intoxication, 818
- Phenelzine**, in psychiatry (CTF) 915
- Phenobarbital**, in pediatrics (CTF) 1008
- Phenothiazines**, teratogenicity, 523
- Phenoxymethylamine**, in urology (CTF) 916
- Phenylalanine**, in psychiatry (CTF) 401
- Phenylbutazone**, in rheumatology (CTF) 299
- Phenylephrine**, in ophthalmology (CTF) 144

- Phenylpropanolamine**, acute psychotic episode, in adverse drug reactions (CTF) 146; CNS reactions, in adverse drug reactions (CTF) 402
- Phenytoin**, elevated serum concentrations in a uremic patient, measured by enzyme-multiplex immunoassay, 386; in dermatology (CTF) 58; in intravenous therapy (CTF) 497, 612; in pediatrics (CTF) 612; in toxicology (CTF) 498
- Pheothrombosis**, complication of barbiturate-induced coma for neuroresuscitation, 601
- Phosphorus**, in general medicine (CTF) 914
- Photosensitivity**, nalidixic acid and sun exposure, 126
- Physical Assessment Series**, thorax and lungs, 166
- Physicians**, prescribing restriction, implications and reactions, 594
- Physostigmine**, in anesthesiology (CTF) 143; in general medicine (CTF) 611; in psychiatry (CTF) 498; in toxicology (CTF) 145
- Piccoro, John J.** (author) book review, 816
- Pindolol**, in cardiovascular disease (CTF) 611
- Pines, Wayne L.** (ed) 75 Years of FDA History, 512
- Pinus, Theodore F.** (coauthor) letter, see **Rich, Darryl S.**, 214
- Piprazine**, treatment of *Ascaris lumbricoides*, 108; treatment of *Enterobius vermicularis*, 106
- Piperidine**, in psychiatry (CTF) 498
- Piroxicam**, absorption with aspirin, 4; in rheumatology (CTF) 706, 1009
- Placenta, John R.** (coauthor) see **Jackson, J. Edward**, 809
- Plasmapheresis**, in hematology (CTF) 611
- Platelet Dysfunction**, in hematology (CTF) 611
- Pneumonia**, *Pneumocystis carinii*, case study, drug therapy, 732
- Pneumococcal Vaccine**, in general medicine (CTF) 220, 399
- Podophyllum**, topical, complications, 279
- Poisoning**, flupenthixol, 388
- Polk, Ron E.** (author) In Vitro Evaluation of a Vancomycin Radioimmunoassay and Observations on Vancomycin Pharmacokinetics in Dialysis Patients, 15; (author) Aminoglycoside Predictions Using a Hand-Held Calculator: Limitations of the Model, 751
- Poliovaccines**, in dermatology (CTF) 297
- Ponte, Charles D.** (author) an unusual presentation for a urinary tract infection, 906; (author) the cut finger syndrome—Intercept® vaginal suppositories, 292; (coauthor) see **Conrad, Kathy**, 1002
- Popovich, Nicholas G.** (coauthor) see **Black, Curtis D.**, 184, 909; (coauthor) letter, author's reply, 697; (coauthor) see **Maanion, James C.**, 248
- Postelink, Michael** (author) case report, penicillin G-induced granulocytopenia, 289
- Potassium**, epidemiology of levels in the elderly, 467
- Potassium Iodide**, in dermatology (CTF) 399; in general medicine (CTF) 496
- Povidone-Iodine**, electrolyte abnormalities following topical therapy, 801; in obstetrics/gynecology (CTF) 221, 497
- Powell, Stephen H.** (coauthor) see **Kaul, Alan F.**, 981
- Prasozin**, hypothermia, in adverse drug reactions (CTF) 222; in cardiovascular disease (CTF) 143, 297, 819, 914; in general medicine (CTF) 59; in pregnancy, 24; in pulmonary disease (CTF) 915
- Prednisolone**, in gastroenterology (CTF) 399, 496
- Prednisone**, in endocrinology (CTF) 58
- Pregnancy**, treatment of hypertension, 21
- Prescription Drug Products List**, released by FDA, 236
- Priling**, National, rise and fall, 392
- Primidone**, in neurology (CTF) 497; in obstetrics/gynecology (CTF) 1008
- Prince, Randall A.** (author) Clinical Trial of Topical Erythromycin in Inflammatory Acne, 372; (author) Comparative Trial of Two Sulfisoxazole Regimens in Acute Urinary Tract Infection, 863; (coauthor) see **Richards, Mark L.**, 341
- Procainamide**, in cardiovascular disease (CTF) 611
- Propranolol**, complete AV block, in adverse drug reactions (CTF) 500; hyperglycemia, 599; hypoglycemia, in adverse drug reactions (CTF) 146; in pregnancy, 23; in cardiovascular disease (CTF) 58; in endocrinology (CTF) 704; in gastroenterology (CTF) 819; in general medicine (CTF) 611; in neurology (CTF) 400, 705; in obstetrics/gynecology (CTF) 705, 1008; in psychiatry (CTF) 401; in renal disease (CTF) 821; metabolism with thyroxine, 131; plasma concentrations and plasmapheresis, 995; retroperitoneal fibrosis, 696; severe diarrhea, 49; toxic interaction with narcotic analgesics, 290
- Propylthiouracil**, hepatic disease, in adverse drug reactions (CTF) 62
- Prostacyclin**, in renal disease (CTF) 706
- Prostaglandin E**, in pediatrics (CTF) 497
- Psychiatry**, psychotic exacerbation with haloperidol, 209; psychiatric drug history chart, 134
- Psychiatry (CTF)**, amoxapine, 299, 401, 915; antiparkinsonian drugs, 498; antipsychotic agents, 221, 299; carbamazepine, 706; clonidine, 401; deanol, 1008; haloperidol, 401, 706; hemodialysis, 820; lithium carbonate, 60, 612; lorazepam, 612; maprotiline, 706; meprobamate, 612; nabilone, 915; naloxone, 401, 1008; phenelzine, 915; phenylalanine, 401; physostigmine, 498; piperidine, 498; propranolol, 401; trazodone, 915; triethylcyclohexanecarboxylate, 298; valproate sodium, 145
- Psychotropic Drugs**, number and type on the Scandinavian market in 1950-1977, 27
- Pulmonary Disease (CTF)**, beclomethasone dipropionate, 145; chlorpheniramine/hydroxyzine, 612; epinephrine, 915; flunisolide, 221; ketotifen, 60; local nasal immunotherapy, 1008; nifedipine, 613; prazosin, 915; primary pulmonary hypertension, 221; salbutamol, 498, 706; terbutaline, 820; theophylline, 145, 299, 820
- Pure Food and Drug Act**, 75th anniversary, 317
- Pyrazinamide**, recommended as OTC, 77; treatment of *Ascaris lumbricoides*, 108; treatment of *Enterobius vermicularis*, 106

Pyridostigmine Bromide, toxic alopecia, in adverse drug reactions (CTF) 222
Pyridoxine, in pediatrics (CTF) 706; in renal disease (CTF) 916
Pyrylmon Pamoate, treatment of *Enterobius vermicularis*, 106

Q

Quinacrine, acute toxic psychosis, in adverse drug reactions (CTF) 710; treatment of *Giardia lamblia*, 107
Quinidine, in cardiovascular disease (CTF) 611
Quinine Dihydrochloride, treatment of parasites, 104

R

Raber, Jack H. (author) reply to letter, 132
Rabies Vaccine, Guillain-Barre syndrome, in adverse drug reactions (CTF) 222
Radiation, used as food preservative, 509
Radioimmunoassay, vancomycin, in vitro evaluation, 15
Rael, Marsha A. (coauthor) see **Bradberry, J. Chris**, 945
Ranitidine, in gastroenterology (CTF) 914; in neurology (CTF) 1007
Rawls, Nathan (author) book review, 911
Regulatory Affairs Professionals Society, objectives of, 926
Reider, Terry L. (author) A Practical Dissertation on the "PD", 205; (coauthor) see **Johnson, June Felice**, 732
Reilly, Kathleen (coauthor) see **Piccolo, John J.**, 816
Renal Disease, cephalosporin-aminoglycoside synergistic nephrotoxicity, 248; elevated serum phenytoin concentrations in a uremic patient, 386
Renal Disease (CTF), activated charcoal, 60; aluminum hydroxide, 145; androgens, 613; ascorbic acid, 60; bendroflumethiazide, 1008; cimetidine, 145, 401; cryoprecipitate, 221; deferoxamine, 60; dopamine, 145; fluosol-DA, 145; heparin, 145; lupus nephritis, 401; methylprednisolone, 821; metronidazole, 60; naproxen, 299; nitroglycerin, 145; propranolol, 821; prostacyclin, 706; pyridoxine, 916; radiocontrast media, 706; valproic acid, 145; vancomycin, 613; zinc chloride, 60
Renal Failure, fenofibrate overdose, 129
Research, issues and priorities in geriatric pharmaceutical care, 111; pharmacy colleges, 318
Research Methodology, 459, 536, 684, 758, 892, 986
Reserpine, in pregnancy, 22
Residencies, locus of control dimensions for pharmacy students election, 43
Retinoids, in dermatology (CTF) 297, 704
Retrolateral Fibrosis, after treatment with propranolol, 696
Reye's Syndrome, in pediatrics (CTF) 612
Rheumatology, combination use of nonsteroidal antiinflammatory drugs, 3
Rheumatology (CTF), auranofin, 145; clotrimazole, 221; colchicine, 60, 613; cyclophosphamide, 60; dapsone, 1008; ibuprofen, 299; indomethacin, 60; levamisole, 401; mannitol, 1008; methylprednisolone, 221, 401; naproxen, 613; phenylbutazone, 299; piroxicam, 706; 1009; salsalate, 145; Seaton, 821; tolmetin, 1009; zinc sulfate, 299
Rich, Darryl S. (author) letter, pharmacokinetics of the 1.73-m² person: are they the same for a 70-kg person?, 214
Richards, Mark L. (author) Antimicrobial Penetration into Cerebrospinal Fluid, 341
Riddiough, Michael A. (author) Winning with Clinical Pharmacy, 267
Rifampin, in infectious disease (CTF) 496
Ritodrine, clinical use, 427; con, 431; dosage and administration, 430; drug evaluation, 425; drug interactions, 430; fetal effect, 430; pharmacokinetics, 426; pharmacology 425; side effects and adverse reactions, 429; toxicity, 429
Ritschel, Gerda (author) book review, 296
Ritschel, W.A. (author) book review, 142, 815
Robbins, Terry S. (author) Actinomycosis: The Disease and its Treatment, 99
Robinson, J. Daniel (author) severe diarrhea secondary to propranolol, 49
Rodriguez, Joe (author) thrombocytopenia associated with mefenamate, 999
Rosaramicin, in infectious disease (CTF) 612
Rosenbloom, David (author) reversible flu-like syndrome, leukopenia, and thrombocytopenia induced by allopurinol, 286
Roy, Myrella T. (author) letter, comment on the comment on nadolol article, 603
Rubella Vaccine, therapeutic abortion, 885
Rubin, Terry N. (author) The Pain Cocktail as an Adjunctive Agent in the Treatment of Spine Pain Patients, 958; (author) urinary hesitancy with L-tryptophan, 996
Ruf, Marcia (coauthor) see **Affrime, Melton B.**, 964
Russell, John V. (author) book review, 140

S

Salbutamol, in pulmonary disease (CTF) 498, 706
Sallylates, Reye's syndrome, in adverse drug reactions (CTF) 300; teratogenicity, 548
Saccharin, on sale for two more years, 828
Sachse, Matr (coauthor) see **Judson, Franklin N.**, 606
Safari, Michael M. (author) acetoxydramic acid—dissolution of urinary stones, 886
Salem, Ronald (author) acute stomatitis associated with doxepin therapy, 992; (coauthor) see **Gots, Vincent P.**, 490
Salinas, Ernest (author) acute ethylene oxide intoxication, 384
Salsalate, in hematology (CTF) 220; in rheumatology (CTF) 145

Saltzman, M.B. (author) letter, comment on aspirin bioavailability article, authors' reply, 53
Sasich, Larry (coauthor) see **Salinas, Ernest**, 384
Sawchuk, Ronald J. (coauthor) see **Matzke, Gary R.**, 386
Sawyer, Dennis (coeditor) Current Therapeutic Findings, 58, 143
Sawyer, William T. (author) letter, authors' reply to aspirin bioavailability, 53
Scandinavia, psychotropic drugs on market 1950-1977, 37
Schell, Ronald F. (coauthor) see **LeFrock, Jack L.**, 951
Schofield, David H. (coauthor) see **Torre, Michael S.**, 175
Schrag, Jerome J. (coauthor) see **Berg, Mary J.**, 180
Schwab, Steven (coauthor) see **General, Joyce A.**, 904
Schwartz, Rowena (coauthor) see **Lee, Mary**, 782
Scopolamine, in general medicine (CTF) 496; in obstetrics/gynecology (CTF) 59
Scott, Steven A. (coauthor) see **Robbins, Terry S.**, 99
Seaton, mussel extract, in rheumatology (CTF) 821
Sector, Russell A. (author) PRN rounds, 1001; (coauthor) see **Payne, Vaughn W.**, 902
Seizures, Febrile, in pediatrics (CTF) 221
Selson Blue Shampoo, in dermatology (CTF) 914
Sheline, Anita (author) letter, comment on Gary L. Dalin's letter, 700
Shimomura, Sam K. (editor) DIAS Rounds, 278, 884
Sibbald, N.J. (coauthor) see **Bayliff, C.D.**, 801
Silver Nitrate, in general medicine (CTF) 220
Skilled Nursing Facilities, proposed conditions of participation, 238
Smith, Gary (coauthor) see **Hendele, Leslie**, 338, 808
Smith, L. (coauthor) see **Baile, G.R.**, 388
Sodium Antimony Gluconate, treatment of parasites, 104
Sodium Bicarbonate, in general medicine (CTF) 143; in toxicology (CTF) 498
Sodium Citrate, in anesthesiology (CTF) 495, 1006
Sodium Hydroxide, in toxicology (CTF) 706
Sohn, Catherine A. (coauthor) see **Tannenbaum, Renee P.**, 766
Somatostatin, in endocrinology (CTF) 611
Speedie, Stuart M. (coauthor) see **Westfall, Lawrence K.**, 777
Spermicides, Vaginal, congenital malformations, in adverse drug reactions, 614
Spirolactone, in endocrinology (CTF) 58; in pregnancy, 22
Spitzer, Thomas Q. (author) comment on nadolol article, 315
Sramek, John J. (coauthor) see **Tornatore, Frank L.**, 209; (author) book review, 394
Steinberg, Marc (coauthor) see **Ponte, Charles D.**, 906
Stetler, C. Joseph (author) Industry's Response to the Drug Regulation System, 799
Stewart, Jesse E. (coauthor) see **Kaczmarek, Elizabeth R.**, 117
Stewart, Ronald B. (author) Epidemiology of Serum Potassium Levels in an Ambulatory Elderly Population: Effect of Age, Sex, Diuretics, and Estimated Creatinine Clearance, 467
Stibocapate, treatment of parasites, 104
Stimmel, Glen L. (author) The Pharmacist as Prescriber of Drug Therapy: The USC Pilot Project, 665
Sittes, S.C. (author) book review, 830
Stranz, Marc H. (author) book review, 217; (author) Metronidazole, 838
Streptokinase, in cardiovascular disease (CTF) 914
Streptozotocin, in oncology (CTF) 400
Strimlan, C. Vaughn (coauthor) see **Covalla, John R.**, 51
Succalfate, adverse reactions, 579; investigational drug information, 578; description, 578; mechanism of action, 578; pharmacology, 579; toxicology, 579
Sudoxicam, absorption with aspirin, 4
Sulfadiazine, in systemic use, 237
Sulfasalazine, in gastroenterology (CTF) 298, 819, 1007; in obstetrics/gynecology (CTF) 299
Sulfapyrazone, acute renal failure, in adverse drug reactions (CTF) 613
Sulfisoxazole, comparative trial of two regimens, 863; in pediatrics (CTF) 221
Sulfonamides, teratogenicity, 551
Sulfonureas, in endocrinology (CTF) 496
Sulindac, agranulocytosis, in adverse drug reactions (CTF) 821; interstitial pneumonitis, in adverse drug reactions (CTF) 1009; nephrotic syndrome, in adverse drug reactions (CTF) 402; pancreatitis, in adverse drug reactions (CTF) 222
Suramin, treatment of parasites, 104
Svenson, Craig K. (ed) Lack of Efficacy of Antacid Tablets—Facts or Fiction?, 120
Sweet Spirits of Nitre, removed for market, 236

T

Taber, Dave (author) comment on antiplatelet pharmacokinetics, 214
Talbert, Robert L. (author) propranolol plasma concentrations and plasmapheresis, 993
Tamoxifen, hypercalcemia, in adverse drug reactions (CTF) 500; in gastroenterology (CTF) 914; in oncology (CTF) 299, 915
Tampons, package warnings, 415
Tannenbaum, Renee P. (author) Preceptors' Views of Community Pharmacy Clerkships: A National Survey, 766
Tartrazine, drugs containing dye, 782
Tatro, David S. (coauthor) see **Safari, Michael M.**, 886
Taylor, A. Thomas (coauthor) see **Longe, R. Leon**, 166
Technicians, Pharmacy, comment on independent national organization, 699; establishing a national organization, 281
Teniposide, in oncology (CTF) 144
Teratogenesis, review of basic principles, discussion of selected agents, Part I, 444; Part II, 542; Part III, 639
Teratogenicity, androgens, 641; antihypertensive agents,

642; antineoplastics, 639; antithyroid and thyroid drugs, 639; congenital infections, 644; estrogens, 641; heavy metals, 644; indomethacin, 642; methylnanthines, 640; paternal drug exposure, 646; D-penicillamine, 642; pesticides, 643; potato blight, 643; progestogens, 642; radiation, 644; smoking, 643; steroids, 641; thalidomide, 642
Terbutaline, hypokalemia, in adverse drug reactions (CTF) 300; in dermatology (CTF) 143; in pulmonary disease (CTF) 820
Tetanus Immune Globulin, in infectious disease (CTF) 59
Tetracycline, intracranial hypertension, in adverse drug reactions (CTF) 710; teratogenicity, 551; treatment of actinomycosis, 101
Tetrahydrocannabinol, in oncology (CTF) 59
Thallium, in toxicology (CTF) 145
Theophylline, comment on overdose, 215; depression, in adverse drug reactions (CTF) 222; in obstetrics/gynecology (CTF) 59; in pediatrics (CTF) 221, 498; in pulmonary disease (CTF) 145, 299, 820; influence of gender on dosage requirements in children with chronic asthma, 338; lack of effect of cimetidine on clearance, 389; urinary retention, in adverse drug reactions (CTF) 500
Thiamine, in pediatrics (CTF) 401
Thiazides, acute cholecystitis, in adverse drug reactions (CTF) 613; in pregnancy, 22
Thies, Harold (coauthor) see **Erlick, Jeffrey Keith**, 133
Thioguanine, in oncology (CTF) 144
Thioisental, anaphylaxis, in adverse drug reactions (CTF) 146; in neurology (CTF) 400
Thorax, physical assessment, 166
Thorsen, Donna J. (author) book review, 137
Thrombocytopenic Purpura, in geriatrics (CTF) 705; in hematology (CTF) 496
Thyroid Hormones, association with breast cancer, in adverse drug reactions (CTF) 62
Thyroxine, metabolism with propranolol, 131
Ticarcillin, in infectious disease (CTF) 221; 914
Tillotson, James R. (coauthor) see **LeFrock, Jack L.**, 951
Tinolol, congestive heart failure, in adverse drug reactions (CTF) 402; in cardiovascular disease (CTF) 611
Tiolidine, in gastroenterology (CTF) 399
Tobacco, oral and pharyngeal cancer, in adverse drug reactions (CTF) 613
Tobramycin, comparative evaluation, 847; in intravenous therapy (CTF) 298
Tolmetin, aseptic meningitis, in adverse drug reactions (CTF) 300; clinical interactions, 5; in rheumatology (CTF) 1009; renal failure, in adverse drug reactions (CTF) 916
Tolbutamide, teratogenicity, 554
Tomasada, Wayne P. (coauthor) see **Rubin, Terry N.**, 958
Toluene, in toxicology (CTF) 145, 613, 916
Torre, Michael S. (author) Glycosylated Hemoglobins and Diabetic Control Assessment, 175
Tornatore, Frank L. (author) psychotic exacerbation with haloperidol, 209
Total Parenteral Nutrition, decreased 1,25-dihydroxycholecalciferol, in adverse drug reactions (CTF) 821; in oncology (CTF) 1008; a study of intravenous emulsion compatibility, 184; use of a hand-held programmable calculator, 54
Toxic Shock Syndrome, in general medicine (CTF) 220
Toxicity, petroleum distillate, 693
Toxicology (CTF), acetaminophen, 222; barium chloride, 1009; benzodiazepines, 821; beryllium tosylate, 222; calcium gluconate, 916; cantharidin, 706; cholestyramine, 706; clonidine, 401; cyanide, 1009; formic acid, 401; gasoline, 222; hydroxyzone, 498; ibuprofen, 300; ipecac syrup, 401; iron, 60; lidocaine, 222; meprobamate, 60; mercury, 401; methaqualone, 613; minoxidil, 401; naloxone, 498; parathion, 821; phenylhydrazine, 145, 998; phenytoin, 498; physostigmine, 145; sodium bicarbonate, 498; sodium hydroxide, 706; thallium, 145; toluene, 145, 613, 916
Tracheobronchitis, with inhalation of isobutyl nitrite, 51
Trazodone, in psychiatry (CTF) 915
Triamcinolone Acetonide, in dermatology (CTF) 914
Triamterene, hyperpyrexia, in adverse drug reaction (CTF) 62; nephrolithiasis, in adverse drug reactions (CTF) 916
Tricyclic Antidepressants see individual agents; in neurology (CTF) 298; in psychiatry (CTF) 498; warning, 319
Trimethoprim, clinical use and pharmacokinetics, 325; gonorrhea, 326; in infectious disease (CTF) 820; lung and respiratory infections, 326; otitis media, 326; resistance, 327; typhoid, 326; urinary tract infections, 326; use in prostatitis, 326
Trimethoprim/Sulfamethoxazole, acute megaloblastic anemia, in adverse drug reactions (CTF) 916; hepatic failure, in adverse drug reactions (CTF) 710; intrahepatic cholestasis, in adverse drug reactions (CTF) 1009; treatment of *Pneumocystis carinii* pneumonia, 733
Trimipramine, in gastroenterology (CTF) 399
Troutman, William G. (author) book review, 218
L-tryptophan, urinary hesitancy with therapeutic doses, 996
Tyrosine, in pediatrics (CTF) 1008

U

Uracil Mustard, in hematology (CTF) 59
Urinary Tract Infection, an unusual presentation, 906; comparative trial of two sulfisoxazole regimens, 863; dosage reduction for bacterial cystitis, 745; oral medications, 740; parenteral drugs, 42; update on treatment, 738
Urology (CTF), BCG, 916; bendroflumethiazide, 300; bethanechol, 145; penicillamine, 300; phenoxymethamine, 916
USP Dispensing Information, availability, Ja-ctr 4; state pharmacies promote, Ja-ctr 3
USP-NF Monographs, added to second supplement, Ja-ctr 2

U.S. Pharmacopoeial Convention, *About Your Medicines*
 endorsed, O-ctr 1; Advisory panel on pharmacy practice, D-ctr 2; Arthur H. Hayes, Jr., appointed to FDA commissioner post, My-ctr 1; availability of USP-DI slide show, JI-ctr 2; bookstore edition of lay language USP-DI, My-ctr 1; Chafetz appointed professor, JI-ctr 2; committee of revision, O-ctr 1; decides against PPI center, Mr-ctr 2; Felix Gorrell elected to board of trustees, Mr-ctr 1; fellowship awards given, JI-ctr 3; fellowships established, Mr-ctr 1; Hayes resigns, JI-ctr 1; Heller awarded honorary degree, JI-ctr 1; launches *About Your Medicines* Newsletter, My-ctr 3; national drug standards day, JI-ctr 1; new members named for advisory panels, My-ctr 2; Provost and Belson join USP staff, D-ctr 1; remarks by LH Fountain, JI-ctr 3; tribute to Paul L. McLain, Mr-ctr 2; USAN 20th anniversary, O-ctr 2; USP XX-NF XV second IRA published, My-ctr 2

V

Vaccines, in geriatrics (CTF) 220
Valium, association with breast cancer, 318
Valproic Acid see also **Valproate Sodium**, asterixis, in adverse drug reactions (CTF) 500; in renal disease (CTF) 145; pancreatitis, in adverse drug reactions (CTF) 710
Valproate Sodium, in psychiatry: (CTF) 145; in neurology (CTF) 221, 497
Vancomycin, evaluation of radioimmunoassay and pharmacokinetics in dialysis patients, 15; in renal disease (CTF) 613
van Dalen, R. (coauthor) see **Vree, T.B.**, 194
Varano, Carmine (author) letter, comments on accolades, 132
Vasopressin, in pediatrics (CTF) 298
Vaughn, Leigh (coauthor) see **Hendele, Leslie**, 338
Venom, supplier defies FDA order, 76
Ventriculitis, treatment with moxalactam, 50
Verapamil, hepatotoxicity, in adverse drug reactions (CTF) 710; in cardiovascular disease (CTF) 399, 611, 914; in pediatrics (CTF) 498
Vidarabine, in pediatrics (CTF) 145
Vincristine, in oncology (CTF) 400; optic atrophy, in adverse drug reactions (CTF) 222
VIPs, Abdellah, Faye, 715; Amith, Lamar, 415; Archambault, George F., 159; Ashbaugh, Richard R., 715; Barker, Kenneth N., 1021; Brandt, Edward N. Jr., 715; Bush, Patricia J., 77, 1021; Byers, Theodore, E., 319; Cady, William J., 77, 415; Davidson, Frances R., 719; Dickinson, James L., 1021; Edwards, S. Albert, 77; Ericson, Avis J., 77; Fine, Jerry, 237; Fine, Max W., 319; Gagnon, Jean Paul, 1021; Garrett, Edward R., 623; Gorup, Colonel Othmar F., 77; Halperin, Jerome A., 830; Hamilton, Richard B., 237; Hardy, Dorcas, 715; Hassan, William, 319; Heller, William M., 237; Holstein, Howard M., 623; Jones, Edith, 319; Kaul, Alan F., 319; Koop, C. Everett, 715; Kushner, Dan, 830; Lamy, Peter P., 415; Leventhal, Robert, 77; Lucas, Commander John, 415, 927; Lyons, Carl, 77; Lyons, John E., 623; Mahaffey, Fred, 1021; Mayer, William E., 927; Moskowitz, Milton S., 237; Murphy, Emaale, 237; Neidinger, Lee M., 415; Nestor, John O., 927; Novitch, Mark, 1021; O'Reilly, James T., 159; Pflig, Solomon C., 319; Pines, Wayne L., 319; Polansky, Murray, 237; Portaro, Denis, 237; Rehder, Terry L., 77; Rodowskas, Christopher, Jr., 1021; Scarlett, Thomas, 380; Schlegel, John F., 1021; Schrader, Rolf K., 237; Schwach, Gene, 830; Sleight, Stephen M., 319; Smith, Dorothy L., 319; Schumacher, Gerald D., 319; Snader, Thomas C., 237; Sively, Robert L., 237; Steeves, Robert, 715; Stockdale, James S., 623; Tatro, David S., 415; Temple, Robert, 319; Thawley, William A., 1021; Thompson, George A., 1021; Valentino, Joseph G., 159; Varano, Carmine, 927; Voigt, John, 830; Wertheimer, Albert L., 319
Vitamin A, in nutrition (CTF) 144
Vitamin B, in nutrition (CTF) 298
Vitamin C, in gastroenterology (CTF) 496; in nutrition (CTF) 400; no adverse effects in megavitamin user, in adverse drug reactions (CTF) 821
Vitamin D, in general medicine (CTF) 704
Vitamin E, in oncology (CTF) 299
Vitaminin, FDA proposal withdrawn, 1020; FDA warning for Nervo Forza[®], 829
Vree, T.B., (author) *The Influence of Urine Flow on Renal Clearance of Creatinine in Patients with Normal and Impaired Kidney Function*, 194; (coauthor) see **Friesen, W.T.**, 325

W

Walkenstein, S. (coauthor) letter, see **Saltzman, M.B.**, 53
Wallace, Sylvia M. (author) *Clinical Application of Pharmacokinetics in Adjusting Gentamicin Dosage*; Case Reports, 651
Walter, C. W. (coauthor) see **Ausman, R. K.**, 440
Ware, John E., Jr. (author) *How to Survey Patient Satisfaction*, 892
Warfarin, cholestatic jaundice, in adverse drug reactions (CTF) 300; in oncology (CTF) 497; unrecognized cause of resistance, 131
Washington News & Comments, 75, 156, 317, 414, 508, 62, 713, 828, 925, 1020
Weinberger, Miles (coauthor) see **Hendele, Leslie**, 338, 808
Weitz, Raphael, (coauthor) see **Cohen, Ian J.**, 388
Wells, Penny A. (author) comment on intravenous emulsion compatibility, 908
Westfall, Larry K. (author) letter, an unrecognized cause of warfarin resistance, 131; (author) *The Effect of Inservice Education Provided by Consultant Pharmacists on the Behavior of Nurses in Long-Term Care Facilities*, 777

Whitney, Harvey A.K., Jr. (ed) *Pharmacy Technicians Establish an Independent National Organization*, 281; (ed) *The Legacy of Donald E. Francke: DCP-A Fifteen-Year Commitment to Clinical Pharmacy*, 990
Wichlinski, Leslaw M. (author) book review, 393
Williamson, Peter M. (coauthor) see **Wolfson, David J.**, 594
Wilson, A.L. (author) *The Treatment of Hypertension in Pregnancy*, 21
Wilson, James L. (coauthor) see **Prince, Randall A.**, 863
Wirth, Carl R. (coauthor) see **LeFrock, Jack L.**, 951
Wiser, Thomas H. (coeditor) see **Svensson, Craig K.**, 120
Wolfson, David J. (author) *Prescribing Restriction: Implications and Reactions*, 594
Wong, Yan Yan (coauthor) see **Talbert, Robert L.**, 993
Woo, Olga F. (author) letter, Michaelis-Menten across the floating bridge, 132

XYZ

Xipamide, in cardiovascular disease (CTF) 220
X-rays, FDA draft report on referral criteria, 1020; reductions yield savings, 621
Yen, Linda R. (author) rubella vaccine, 885
Yesalis, Charles E. (coauthor) see **Helling, Dennis K.**, 581; (coauthor) see **Norwood, G. Joseph**, 656
Zelnio, Robert N. (author) diabetic urine testing in South Carolina, 292
Zinc Chloride, in renal disease (CTF) 60
Zinc Sulfate, in dermatology (CTF) 220; in geriatrics (CTF) 1007; in rheumatology (CTF) 299
Zomepirac, anaphylactic reaction, in adverse drug reactions (CTF) 710; in general medicine (CTF) 220, 298; in neurology (CTF) 1007; new drug evaluation, 522

ADVERTISERS

American Society of Hospital Pharmacists, IPA, Fe-ibc; S-717; N-920; Pan Pacific II, N-883
Association of Pharmacy Technicians, API, Ap-ibc; JI-ibc; N-901
Bristol Laboratories, Cefadyl, Ja-ibc; Fe-155; Mr-239; Ap-301; My-371; Mexate, Ja-41-42; Fe-123, 124; Ap-245, 246; My-323, 324; JI-615, 616; S-631, 632; O-825, 826; N-881, 882
Bristol Royal Infirmary, 8th National Conference for Information Pharmacists, Ap-303; JI-609
Burroughs Wellcome Co., Septra DS, Ja-38-40; Mr-230-232
Canadian Pharmaceutical Association, CPS '81, Mr-200; CSM, Mr-228
Cedpharm, Information-Cedpharm, Ap-244; My-413
Drug Intelligence and Clinical Pharmacy, address change, O-788; N-919; AID, Ja-71; Fe-84, 152; Mr-234; My-412; JI-620; S-712; N-922; Bound Volumes, Mr-226; Ap-303

My-405; Je-507; JI-617; O-776; N-837; L'Informateur Farmaceutico, S-719; N-924; microfilm, Je-504; N-919; missing copy policy, Ma-376; O-728; N-924; **PharmACE** 81, Ja-74; Fe-ibc; Mr-ibc; Ap-243; My-ibc; Je-ibc; JI-ibc; S-ibc; O-723; N-835; D-1019; Repertorio Terapeutico, Fe-116; Je-520; N-899; Reprints, Mr-226; Je-507; S-720; O-776; N-837; Stethoscopic Heart Records, JI-614; O-807; N-907; Subscription Information, Fe-ibc; Mr-ibc; Ap-ibc; My-ibc; Je-ibc; JI-ibc; S-ibc; N-ibc; O-ibc; D-ibc

Harvey Whitney Books, *The Practice of Pharmacy*, Fe-92-93; Mr-240, ibc; Ap-304, 305; My-369, 370; Je-ibc; JI-597; S-692; O-750; N-ibc; D-ibc; **Psychotropic Drug Handbook**, Fe-110; Mr-183; Ap-282; My-402; Je-433; S-655; O-757; N-891

International Pharmaceutical Federation, Biopharmaceutics and Pharmacokinetics Symposium, JI-609; O-788; N-924
El Lilly and Company, Drug Information Center, Ja-79, 80, ibc; Fe-89-91; Kefzol, Ja-ibc; Fe-125; Mr-165; Ap-ibc; Je-499, 500; JI-519, 520; S-709, 710; O-775, 776; N-923, 924; Mandol, Mr-206, 207; My-404, 405; JI-608, 609; S-718, 719; N-836, 837; Nebcin, Ap-312-314; Je-464-466; O-812-814; D-1010-1012; "Satellite pharmacists", Ja-80, ibc; Fe-90, 91
Merrell-Dow Laboratories, Bityl, Ja-61-62; Fe-122; Mr-198, 199; Ap-282, 283; S-720, 721; O-832, ibc; D-1013-1015; Chronulac, Ja-68-70; Mr-224-226; S-690-692; O-726-728

Miles Pharmaceuticals, Mezlin, N-878-880; D-978-980
Mount Sinai School of Medicine, Morphine Symposium, 672

Personnel Placement, 71, 152, 228, 229, 306, 307, 308, 399, 397, 405, 406, 410, 506, 507, 617, 707, 708, 720, 827, 832, 919, 1016

Roche Laboratories, Roche Honors, Mr-407-409; Je-501-503; S-688-689; "Speaking Professionally," Ja-56-57; Fe-150, 151; Ap-310, 311; O-724, 725; N-876, 877; D-1004, 1005

Smith, Kline & French Laboratories, Hospital Pharmacy Services, Fe-149; My-ibc; S-673
E.R. Squibb & Sons, Inc., Capoten, Je-421-424; JI-515-518; S-627-630; Corgard, Ja-63-66; Fe-85-88; Mr-201-204

Sylla Company, Emit Assays, O-ibc; N-ibc; D-ibc
Uppsala University, Conference on the Impact of Computer Technology on Drug Information, Je-473

INDEX ABBREVIATIONS

ab: abstract
 CTF: Current Therapeutic Findings
 ctr: center insert
 ibc: inside back cover
 ifc: inside front cover
 obc: outside back cover

U.S. POSTAL SERVICE STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685)			
1. TITLE OF PUBLICATION DRUG INTELLIGENCE AND CLINICAL PHARMACY	2. PUBLICATION NO. 0 0 1 2 3 4 5 6 7 8	3. DATE OF FILING 30 Sep 81	
4. FREQUENCY OF ISSUE Monthly (July and August combined)	5. A. NO. OF ISSUES PUBLISHED ANNUALLY 11	6. ANNUAL SUBSCRIPTION PRICE \$26.00	
7. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP Code) (Not printer)			
4906 Cooper Road, P. O. Box 42435, Cincinnati, OH 45242			
8. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not printer)			
Same			
9. FULL NAME AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR (This name MUST NOT be blank)			
PUBLISHER (Name and Complete Mailing Address) Harvey A. K. Whitney, Jr., 4906 Cooper Road, P. O. Box 42435, Cincinnati, OH 45242			
EDITOR (Name and Complete Mailing Address) Same			
MANAGING EDITOR (Name and Complete Mailing Address) Same			
10. OWNERSHIP (If ownership is a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a partnership or other unincorporated firm, its name and address must be stated. (This must be completed)			
FULL NAME COMPLETE MAILING ADDRESS			
Drug Intelligence and Clinical Pharmacy P. O. Box 42435			
A Nonprofit Corporation Cincinnati, OH 45242			
11. IF NOT OWNED BY A CORPORATION, PARTNERSHIP, OR OTHER UNINCORPORATED FIRM, STATE THE NAMES AND ADDRESSES OF ALL STOCKHOLDERS OR OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES OF WHICH THERE ARE NONE, OR NONE			
FULL NAME COMPLETE MAILING ADDRESS			
NONE			
12. FOR COMPLETION BY NON-PROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 412.5, USPS 1980) (If checked, publisher must submit explanation of charges with this statement)			
13. IF NOT CHECKED DURING PRECEDING 12 MONTHS, IF CHECKED DURING PRECEDING 12 MONTHS			
14. EXTENT AND NATURE OF CIRCULATION			
A. TOTAL NO. COPIES (Net Press Run)		9665	
B. PAID CIRCULATION (Include paid circulation and carrier street sales)		0	
C. MAIL SUBSCRIPTIONS		8797	
D. TOTAL PAID CIRCULATION (Sum of B and C)		8797	
E. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS (Samples, complimentary, and other free copies)		810	
F. TOTAL DISTRIBUTION (Sum of D and E)		9607	
G. COPIES NOT DISTRIBUTED (Leftovers, unsold, unaccounted for, etc.)		58	
H. RETURN FROM NEWS AGENTS		0	
I. TOTAL (Sum of F and H) (Must equal net press run in 14)		9665	
J. COPIES AND TITLE OF PUBLICATION (Not for circulation)		9675	
15. I certify that the statements made by me above are correct and complete			
Signature of Owner or Editor			

